Identification
NameDocetaxel
Accession NumberDB01248  (APRD00932)
TypeSmall Molecule
GroupsApproved, Investigational
Description

Docetaxel is a clinically well established anti-mitotic chemotherapy medication used mainly for the treatment of breast, ovarian, and non-small cell lung cancer. Docetaxel binds to microtubules reversibly with high affinity and has a maximum stoichiometry of one mole docetaxel per mole tubulin in microtubules.

Structure
Thumb
Synonyms
Docetaxel anhydrous
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
TXL
External IDs RP-6976
Product Ingredients
IngredientUNIICASInChI KeyDetails
Docetaxel trihydrate15H5577CQD 148408-66-6XCDIRYDKECHIPE-QHEQPUDQSA-NDetails
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocefrezKitSun Pharma Global FZE2011-05-032017-02-03Us
DocetaxelInjection, solution, concentrate160 mg/8mLIntravenousWinthrop U.S.2016-10-23Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousAccord Healthcare Limited2013-05-15Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousSandoz2011-06-29Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/2mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-06-232017-08-31Us
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousWinthrop U.S.2010-10-21Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma Company2014-09-01Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousSandoz2015-07-22Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousNorth Star Rx Llc2016-01-01Not applicableUs
DocetaxelInjection, solution, concentrate80 mg/8mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-06-232017-08-31Us
DocetaxelInjection, solution, concentrate80 mg/4mLIntravenousWinthrop U.S.2010-10-21Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma Company2014-09-01Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-28Not applicableUs
DocetaxelInjection, solution80 mg/4mLIntravenousNorth Star Rx Llc2016-01-01Not applicableUs
DocetaxelInjection, solution, concentrate200 mg/20mLIntravenousPfizer Laboratories Div Pfizer Inc.2014-06-232017-04-30Us
DocetaxelKitAccord Healthcare Limited2011-06-30Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma Company2014-09-01Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-28Not applicableUs
DocetaxelInjection, solution10 mg/mLIntravenousHospira, Inc.2011-03-08Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2017-03-28Not applicableUs
DocetaxelKitAccord Healthcare Limited2011-06-30Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousActavis Pharma Company2015-10-13Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousHospira, Inc.2016-06-28Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousAccord Healthcare Limited2012-07-01Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousMc Kesson Packaging Services A Buisness Unit Of Mc Kesson Corporation2011-06-08Not applicableUs
Docetaxel InjectionSolution20 mgIntravenousBiolyse Pharma CorporationNot applicableNot applicableCanada
Docetaxel InjectionSolution10 mgIntravenousSandoz Canada Incorporated2016-06-02Not applicableCanada
Docetaxel InjectionSolution20 mgIntravenousTeva2014-03-28Not applicableCanada
Docetaxel InjectionSolution20 mgIntravenousAccord Healthcare Limited2015-02-27Not applicableCanada
Docetaxel InjectionSolution80 mgIntravenousTeva2014-03-28Not applicableCanada
Docetaxel Injection USPSolution10 mgIntravenousHospira, Inc.2011-03-01Not applicableCanada
Docetaxel Non-alcohol FormulaInjection20 mg/mLIntravenousEagle Pharmaceuticals, Inc.2016-01-15Not applicableUs
Docetaxel WinthropInjection, solution, concentrate20 mg/1mlIntravenousAventis Pharma Ltd.2007-04-20Not applicableEu
Docetaxel WinthropInjection, solution, concentrate80 mg/4mlIntravenousAventis Pharma Ltd.2007-04-20Not applicableEu
Docetaxel WinthropInjection, solution, concentrate160 mg/8mlIntravenousAventis Pharma Ltd.2007-04-20Not applicableEu
PMS-docetaxelKit; Solution20 mgIntravenousPharmascience IncNot applicableNot applicableCanada
PMS-docetaxelKit; Solution80 mgIntravenousPharmascience IncNot applicableNot applicableCanada
TaxotereInjection, solution, concentrate80 mg/4mlIntravenousAventis Pharma Ltd.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate80 mg/4mLIntravenousSanofi Aventis2010-08-02Not applicableUs
TaxotereInjection, solution, concentrate160 mg/8mlIntravenousAventis Pharma Ltd.1995-11-27Not applicableEu
TaxotereSolution20 mgIntravenousSanofi Aventis1995-12-31Not applicableCanada
TaxotereSolution80 mgIntravenousSanofi Aventis1995-12-31Not applicableCanada
TaxotereInjection, solution, concentrate20 mg/0.5mlIntravenousAventis Pharma Ltd.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate80 mg/2mlIntravenousAventis Pharma Ltd.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate20 mg/1mlIntravenousAventis Pharma Ltd.1995-11-27Not applicableEu
TaxotereInjection, solution, concentrate20 mg/mLIntravenousSanofi Aventis2010-08-02Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousX Gen Pharmaceuticals, Inc.2017-04-17Not applicableUs
DocetaxelInjection, solution, concentrate80 mg/4mLIntravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousX Gen Pharmaceuticals, Inc.2017-04-17Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr Reddy's Laboratories2014-11-10Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousX Gen Pharmaceuticals, Inc.2017-04-17Not applicableUs
DocetaxelInjection, solution20 mg/mLIntravenousDr Reddy's Laboratories2014-11-10Not applicableUs
DocetaxelSolution20 mg/mLIntravenousSagent Pharmaceuticals2013-07-012017-03-31Us
DocetaxelInjection, solution, concentrate40 mg/mLIntravenousJiangsu Hengrui Medicine Co., Ltd.2017-02-15Not applicableUs
DocetaxelInjection, solution, concentrate20 mg/mLIntravenousTeva Parenteral Medicines, Inc.2015-12-31Not applicableUs
Docetaxel AccordInjection, solution, concentrate20 mg/1mlIntravenousAccord Healthcare Limited2012-05-22Not applicableEu
Docetaxel AccordInjection, solution, concentrate80 mg/4mlIntravenousAccord Healthcare Limited2012-05-22Not applicableEu
Docetaxel AccordInjection, solution, concentrate160 mg/8mlIntravenousAccord Healthcare Limited2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate180 mg/9mlIntravenousFresenius Kabi Oncology Plc.2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate20 mg/1mlIntravenousFresenius Kabi Oncology Plc.2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate80 mg/4mlIntravenousFresenius Kabi Oncology Plc.2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate120 mg/6mlIntravenousFresenius Kabi Oncology Plc.2012-05-22Not applicableEu
Docetaxel KabiInjection, solution, concentrate160 mg/8mlIntravenousFresenius Kabi Oncology Plc.2012-05-22Not applicableEu
TaxespiraInjection, solution, concentrate80 mg/4mlIntravenousHospira, Inc.2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate120 mg/6mlIntravenousHospira, Inc.2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate140 mg/7mlIntravenousHospira, Inc.2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate160 mg/8mlIntravenousHospira, Inc.2015-08-28Not applicableEu
TaxespiraInjection, solution, concentrate20 mg/1mlIntravenousHospira, Inc.2015-08-28Not applicableEu
Approved Over the Counter ProductsNot Available
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Docetaxel MylanInjection, solution, concentrate200 mg/10mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate20 mg/1mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate20 mg/1mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate80 mg/4mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate80 mg/4mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel MylanInjection, solution, concentrate200 mg/10mlIntravenousMylan S.A.S.2012-01-31Not applicableEu
Docetaxel Teva PharmaInjection, solution, concentrate80 mgIntravenousTeva Pharma B.V.  2011-01-21Not applicableEu
Docetaxel Teva PharmaInjection, solution, concentrate20 mgIntravenousTeva Pharma B.V.  2011-01-21Not applicableEu
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII699121PHCA
CAS number114977-28-5
WeightAverage: 807.8792
Monoisotopic: 807.346605409
Chemical FormulaC43H53NO14
InChI KeyZDZOTLJHXYCWBA-VCVYQWHSSA-N
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
IUPAC Name
(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(acetyloxy)-15-{[(2R,3S)-3-{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1,9,12-trihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0³,¹⁰.0⁴,⁷]heptadec-13-en-2-yl benzoate
SMILES
[H][C@@]12C[[email protected]](O)[C@@]3(C)C(=O)[[email protected]](O)C4=C(C)[[email protected]](C[C@@](O)([C@@H](OC(=O)C5=CC=CC=C5)[C@]3([H])[C@@]1(CO2)OC(C)=O)C4(C)C)OC(=O)[[email protected]](O)[C@@H](NC(=O)OC(C)(C)C)C1=CC=CC=C1
Pharmacology
Indication

For the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Also used as a single agent in the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. It is also used in combination with prednisone, in the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer. Furthermore, docetaxel has uses in the treatment of gastric adenocarinoma and head and neck cancer.

Structured Indications
Pharmacodynamics

Docetaxel is a taxoid antineoplastic agent. It promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, docetaxel induces abnormal arrays or "bundles" of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.

Mechanism of action

Docetaxel interferes with the normal function of microtubule growth. Whereas drugs like colchicine cause the depolymerization of microtubules in vivo, docetaxel arrests their function by having the opposite effect; it hyper-stabilizes their structure. This destroys the cell's ability to use its cytoskeleton in a flexible manner. Specifically, docetaxel binds to the β-subunit of tubulin. Tubulin is the "building block" of mictotubules, and the binding of docetaxel locks these building blocks in place. The resulting microtubule/docetaxel complex does not have the ability to disassemble. This adversely affects cell function because the shortening and lengthening of microtubules (termed dynamic instability) is necessary for their function as a transportation highway for the cell. Chromosomes, for example, rely upon this property of microtubules during mitosis. Further research has indicated that docetaxel induces programmed cell death (apoptosis) in cancer cells by binding to an apoptosis stopping protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function.

TargetKindPharmacological actionActionsOrganismUniProt ID
Tubulin beta-1 chainProteinyesNot AvailableHumanQ9H4B7 details
Apoptosis regulator Bcl-2ProteinunknownNot AvailableHumanP10415 details
Microtubule-associated protein 2ProteinyesNot AvailableHumanP11137 details
Microtubule-associated protein 4ProteinyesNot AvailableHumanP27816 details
Microtubule-associated protein tauProteinyesNot AvailableHumanP10636 details
Nuclear receptor subfamily 1 group I member 2Proteinunknown
binder
HumanO75469 details
Related Articles
Absorption

The pharmacokinetic profile is consistent with a three-compartment model. The area under the curve (AUC) was dose proportional following doses of 70 mg/m2 to 115 mg/m2 with infusion times of 1 to 2 hours.

Volume of distribution

The initial rapid decline represents distribution to the peripheral compartments and the late (terminal) phase is due, in part, to a relatively slow efflux of docetaxel from the peripheral compartment. * 113 L

Protein binding

In vitro studies show that 94% protein bound, mainly to a1-acid glycoprotein, albumin, and lipoproteins. When measured in cancer patients, docetaxel is 97% bound to plasma protein. Dexamethasone does not affect the protein binding of docetaxel.

Metabolism

Hepatic. In vitro drug interaction studies revealed that docetaxel is metabolized by the CYP3A4 isoenzyme (1 major, 3 minor metabolites).

Route of elimination

Docetaxel was eliminated in both the urine and feces following oxidative metabolism of the tert-butyl ester group, but fecal excretion was the main elimination route. Within 7 days, urinary and fecal excretion accounted for approximately 6% and 75% of the administered radioactivity, respectively.

Half life

Dose-dependent. Doses of 70 mg per square meter of body surface area (mg/m 2 ) or higher produce a triphasic elimination profile. With lower doses, assay limitations precluded detection of the terminal elimination phase. The half-life of the alpha, beta, and gamma phase are 4 minutes, 36 minutes, and 11.1 hours, respectively.

Clearance
  • 21 L/h/m2 [Total body clearance, cancer patients after IV administration of 20–115 mg/m2]
Toxicity

Oral LD50 in rat is >2000 mg/kg. Anticipated complications of overdosage include: bone marrow suppression, peripheral neurotoxicity, and mucositis. In two reports of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both patients experienced severe neutropenia, mild asthenia, cutaneous reactions, and mild paresthesia, and recovered without incident.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Docetaxel Action PathwayDrug actionSMP00435
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Canalicular multispecific organic anion transporter 1---(G;G) / (C;G)G Allele ADR Directly StudiedLeukopenia, neutropenia Details
Interactions
Drug Interactions
DrugInteractionDrug group
2-(4-Chlorophenyl)-5-QuinoxalinecarboxamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-(4-Chlorophenyl)-5-Quinoxalinecarboxamide.Experimental
2-HYDROXY-1,4-NAPHTHOQUINONEThe metabolism of Docetaxel can be decreased when combined with 2-HYDROXY-1,4-NAPHTHOQUINONE.Experimental
2-MethoxyestradiolThe risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyestradiol.Investigational
3-MethoxybenzamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3-Methoxybenzamide.Experimental
3,4-Dihydroxybenzoic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with 3,4-Dihydroxybenzoic Acid.Experimental
7-HydroxystaurosporineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 7-Hydroxystaurosporine.Experimental
8-azaguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with 8-azaguanine.Experimental
AbirateroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Abiraterone.Approved
ABT-263The risk or severity of adverse effects can be increased when Docetaxel is combined with ABT-263.Investigational
AcetaminophenThe serum concentration of Docetaxel can be increased when it is combined with Acetaminophen.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved
AclarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aclarubicin.Investigational
AfatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afatinib.Approved
AfimoxifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Afimoxifene.Investigational
AfliberceptThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aflibercept.Approved
AlatrofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alatrofloxacin.Withdrawn
AlbendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole.Approved, Vet Approved
AldesleukinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aldesleukin.Approved
AldosteroneThe serum concentration of Docetaxel can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Docetaxel can be increased when it is combined with Alectinib.Approved
AlemtuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alemtuzumab.Approved, Investigational
AlfentanilThe serum concentration of Docetaxel can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alitretinoin.Approved, Investigational
Alpha-DifluoromethylornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Alpha-Difluoromethylornithine.Experimental
AltretamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Altretamine.Approved
AmantadineThe serum concentration of Docetaxel can be increased when it is combined with Amantadine.Approved
AminoglutethimideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminoglutethimide.Approved
Aminohippuric acidThe serum concentration of Docetaxel can be increased when it is combined with Aminohippuric acid.Approved
Aminolevulinic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Aminolevulinic acid.Approved
AmiodaroneThe metabolism of Docetaxel can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Docetaxel can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Docetaxel can be increased when it is combined with Amlodipine.Approved
AmonafideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amonafide.Investigational
Amphotericin BThe metabolism of Docetaxel can be decreased when combined with Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Docetaxel can be decreased when it is combined with Amprenavir.Approved
AmrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amrubicin.Approved, Investigational
AmsacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Amsacrine.Approved
AN2690The metabolism of Docetaxel can be decreased when combined with AN2690.Investigational
AnagrelideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anagrelide.Approved
AnastrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Anastrozole.Approved, Investigational
AnidulafunginThe metabolism of Docetaxel can be decreased when combined with Anidulafungin.Approved, Investigational
AprepitantThe serum concentration of Docetaxel can be increased when it is combined with Aprepitant.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Docetaxel can be decreased when combined with Artemether.Approved
AsparaginaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Asparaginase.Approved
AstemizoleThe serum concentration of Docetaxel can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Docetaxel can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Docetaxel can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Docetaxel can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Docetaxel can be increased when it is combined with Atorvastatin.Approved
AxitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Axitinib.Approved, Investigational
AzacitidineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azacitidine.Approved, Investigational
AzathioprineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azathioprine.Approved
Azelaic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Azelaic Acid.Approved
AzelastineThe serum concentration of Docetaxel can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Docetaxel can be increased when it is combined with Azithromycin.Approved
Bafilomycin A1The metabolism of Docetaxel can be decreased when combined with Bafilomycin A1.Experimental
BatimastatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Batimastat.Experimental
BelinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Belinostat.Approved, Investigational
BendamustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bendamustine.Approved, Investigational
BenzocaineThe serum concentration of Docetaxel can be increased when it is combined with Benzocaine.Approved
Benzoic AcidThe metabolism of Docetaxel can be decreased when combined with Benzoic Acid.Approved
BepridilThe serum concentration of Docetaxel can be increased when it is combined with Bepridil.Approved, Withdrawn
BesifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Besifloxacin.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
BexaroteneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bexarotene.Approved, Investigational
BicalutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bicalutamide.Approved
BifonazoleThe metabolism of Docetaxel can be decreased when combined with Bifonazole.Approved
BiperidenThe serum concentration of Docetaxel can be increased when it is combined with Biperiden.Approved
BleomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bleomycin.Approved
BlinatumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Blinatumomab.Approved
BoceprevirThe metabolism of Docetaxel can be decreased when combined with Boceprevir.Approved, Investigational
BortezomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Docetaxel can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Bosutinib.Approved
Brentuximab vedotinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Brentuximab vedotin.Approved
BromocriptineThe serum concentration of Docetaxel can be increased when it is combined with Bromocriptine.Approved, Investigational
BuprenorphineThe serum concentration of Docetaxel can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Docetaxel can be increased when it is combined with Buspirone.Approved, Investigational
BusulfanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Busulfan.Approved, Investigational
ButenafineThe metabolism of Docetaxel can be decreased when combined with Butenafine.Approved
ButoconazoleThe metabolism of Docetaxel can be decreased when combined with Butoconazole.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabazitaxel.Approved
CabergolineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabergoline.Approved
CabozantinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cabozantinib.Approved
CaffeineThe serum concentration of Docetaxel can be increased when it is combined with Caffeine.Approved
CalcipotriolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Calcipotriol.Approved
CamptothecinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Camptothecin.Experimental
CanagliflozinThe serum concentration of Docetaxel can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Docetaxel can be increased when it is combined with Candesartan.Approved
CandicidinThe metabolism of Docetaxel can be decreased when combined with Candicidin.Withdrawn
CapecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Capecitabine.Approved, Investigational
CaptoprilThe serum concentration of Docetaxel can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Docetaxel can be increased when combined with Carbamazepine.Approved, Investigational
CarboplatinCarboplatin may increase the myelosuppressive activities of Docetaxel.Approved
Carbopol 974PThe risk or severity of adverse effects can be increased when Docetaxel is combined with polyacrylic acid.Investigational
CarfilzomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carfilzomib.Approved
CarmofurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmofur.Withdrawn
CarmustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Carmustine.Approved
CarvedilolThe serum concentration of Docetaxel can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe metabolism of Docetaxel can be decreased when combined with Caspofungin.Approved
CediranibThe risk or severity of adverse effects can be increased when Docetaxel is combined with AZD2171.Investigational
CelecoxibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Docetaxel can be increased when it is combined with Ceritinib.Approved
CeruleninThe metabolism of Docetaxel can be decreased when combined with Cerulenin.Approved
CetuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cetuximab.Approved
ChlorambucilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorambucil.Approved
ChloroquineThe serum concentration of Docetaxel can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorotrianiseneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorotrianisene.Withdrawn
ChloroxineThe metabolism of Docetaxel can be decreased when combined with Chloroxine.Approved
ChlorpromazineThe serum concentration of Docetaxel can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Docetaxel can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Docetaxel can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Docetaxel can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Docetaxel can be decreased when it is combined with Cholic Acid.Approved
CiclopiroxThe metabolism of Docetaxel can be decreased when combined with Ciclopirox.Approved, Investigational
CilazaprilThe serum concentration of Docetaxel can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Docetaxel can be decreased when it is combined with Cimetidine.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ciprofloxacin.Approved, Investigational
CisplatinCisplatin may increase the myelosuppressive activities of Docetaxel.Approved
CitalopramThe serum concentration of Docetaxel can be increased when it is combined with Citalopram.Approved
CladribineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cladribine.Approved, Investigational
ClarithromycinThe metabolism of Docetaxel can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Docetaxel can be decreased when combined with Clemastine.Approved
ClofarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clofarabine.Approved, Investigational
ClofazimineThe serum concentration of Docetaxel can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Docetaxel can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Docetaxel can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Clozapine.Approved
CobicistatThe metabolism of Docetaxel can be decreased when combined with Cobicistat.Approved
ColchicineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Colchicine.Approved
ColforsinThe serum concentration of Docetaxel can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Docetaxel can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
CyclosporineThe metabolism of Docetaxel can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cyproterone acetate.Approved, Investigational
CytarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine.Approved, Investigational
DabrafenibThe serum concentration of Docetaxel can be decreased when it is combined with Dabrafenib.Approved
DacarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dacarbazine.Approved, Investigational
DaclatasvirThe serum concentration of Docetaxel can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dactinomycin.Approved
DaratumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daratumumab.Approved
DarunavirThe metabolism of Docetaxel can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Docetaxel can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Daunorubicin.Approved
Decanoic AcidThe metabolism of Docetaxel can be decreased when combined with Decanoic Acid.Experimental
DecitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Decitabine.Approved, Investigational
DeferasiroxThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Docetaxel can be decreased when combined with Delavirdine.Approved
Denileukin diftitoxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Denileukin diftitox.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Docetaxel.Approved
DesipramineThe serum concentration of Docetaxel can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Docetaxel.Approved
DesloratadineThe serum concentration of Docetaxel can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexrazoxaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dexrazoxane.Approved, Withdrawn
DextromethorphanThe serum concentration of Docetaxel can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Docetaxel can be increased when it is combined with Diclofenac.Approved, Vet Approved
DienogestThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dienogest.Approved
DiethylstilbestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Diethylstilbestrol.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Docetaxel.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Docetaxel.Approved
DihydroergotamineThe metabolism of Docetaxel can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Docetaxel can be decreased when combined with Diltiazem.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Dinutuximab.Approved
DipyridamoleThe serum concentration of Docetaxel can be increased when it is combined with Dipyridamole.Approved
DoxazosinThe serum concentration of Docetaxel can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Docetaxel can be increased when it is combined with Doxepin.Approved
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Docetaxel.Approved, Investigational
DoxorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Docetaxel can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Docetaxel can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe serum concentration of Docetaxel can be increased when it is combined with Dronedarone.Approved
EcabetThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ecabet.Approved, Investigational
EconazoleThe metabolism of Docetaxel can be decreased when combined with Econazole.Approved
EfavirenzThe serum concentration of Docetaxel can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe metabolism of Docetaxel can be decreased when combined with Efinaconazole.Approved
EflornithineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eflornithine.Approved, Withdrawn
EG009The risk or severity of adverse effects can be increased when Docetaxel is combined with EG009.Investigational
ElbasvirThe serum concentration of Docetaxel can be increased when it is combined with Elbasvir.Approved
ElsamitrucinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Elsamitrucin.Investigational
EltrombopagThe serum concentration of Docetaxel can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Docetaxel can be increased when it is combined with Enalapril.Approved, Vet Approved
EnoxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Docetaxel can be decreased when it is combined with Enzalutamide.Approved
EpirubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epirubicin.Approved
Epothilone BThe risk or severity of adverse effects can be increased when Docetaxel is combined with Epothilone B.Experimental, Investigational
ErgonovineThe serum concentration of Docetaxel can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Docetaxel can be increased when it is combined with Ergotamine.Approved
EribulinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Eribulin.Approved, Investigational
ErlotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Erlotinib.Approved, Investigational
ErythromycinThe metabolism of Docetaxel can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Docetaxel can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstramustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Estramustine.Approved
EstriolThe serum concentration of Docetaxel can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Docetaxel can be decreased when it is combined with Estrone.Approved
Ethiodized oilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethiodized oil.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ethyl carbamate.Withdrawn
EtoposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.Approved
EtravirineThe serum concentration of Docetaxel can be decreased when it is combined with Etravirine.Approved
EverolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus.Approved
ExemestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Exemestane.Approved, Investigational
FelodipineThe serum concentration of Docetaxel can be increased when it is combined with Felodipine.Approved, Investigational
FenretinideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fenretinide.Investigational
FentanylThe serum concentration of Docetaxel can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe serum concentration of Docetaxel can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Docetaxel can be increased when it is combined with Fidaxomicin.Approved
FingolimodDocetaxel may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FlavopiridolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flavopiridol.Experimental, Investigational
FleroxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fleroxacin.Approved
FloxuridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Floxuridine.Approved
FluconazoleThe metabolism of Docetaxel can be decreased when combined with Fluconazole.Approved
FlucytosineThe metabolism of Docetaxel can be decreased when combined with Flucytosine.Approved
FludarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fludarabine.Approved
FlumequineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flumequine.Withdrawn
FluorouracilThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Docetaxel can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Docetaxel can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Docetaxel can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Docetaxel can be increased when it is combined with Flurazepam.Approved, Illicit
FlutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Flutamide.Approved
FluvoxamineThe metabolism of Docetaxel can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formestane.Approved, Investigational, Withdrawn
FormycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Formycin.Experimental
FosamprenavirThe metabolism of Docetaxel can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Docetaxel can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Docetaxel can be increased when combined with Fosphenytoin.Approved
FotemustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fotemustine.Experimental
FulvestrantThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fulvestrant.Approved, Investigational
FumagillinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Fumagillin.Experimental
Fusidic AcidThe serum concentration of Docetaxel can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Docetaxel is combined with G17DT.Investigational
Gallium nitrateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gallium nitrate.Approved, Investigational
GatifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gatifloxacin.Approved, Investigational
GefitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib.Approved, Investigational
GeldanamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Geldanamycin.Experimental
GemcitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemcitabine.Approved
GemifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Gemtuzumab ozogamicin.Approved, Investigational, Withdrawn
GenisteinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Genistein.Investigational
Ginsenoside CThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ginsenoside C.Nutraceutical
GlyburideThe serum concentration of Docetaxel can be increased when it is combined with Glyburide.Approved
GlyphosateThe metabolism of Docetaxel can be decreased when combined with Glyphosate.Experimental
GoserelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Goserelin.Approved
Gramicidin DThe serum concentration of Docetaxel can be increased when it is combined with Gramicidin D.Approved
GrepafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Grepafloxacin.Withdrawn
GriseofulvinThe metabolism of Docetaxel can be decreased when combined with Griseofulvin.Approved, Vet Approved
HadacidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hadacidin.Experimental
HalofuginoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Halofuginone.Investigational, Vet Approved
HaloperidolThe serum concentration of Docetaxel can be increased when it is combined with Haloperidol.Approved
HaloproginThe metabolism of Docetaxel can be decreased when combined with Haloprogin.Approved, Withdrawn
HexestrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hexestrol.Withdrawn
HexetidineThe metabolism of Docetaxel can be decreased when combined with Hexetidine.Approved
HydrocortisoneThe serum concentration of Docetaxel can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
Hydroxyprogesterone caproateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyprogesterone caproate.Approved
HydroxyureaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ibrutinib.Approved
IdarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Idarubicin.Approved
IdelalisibThe serum concentration of Docetaxel can be increased when it is combined with Idelalisib.Approved
IfosfamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ifosfamide.Approved
ImatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib.Approved
ImipramineThe serum concentration of Docetaxel can be increased when it is combined with Imipramine.Approved
ImiquimodThe risk or severity of adverse effects can be increased when Docetaxel is combined with Imiquimod.Approved, Investigational
IndinavirThe metabolism of Docetaxel can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Docetaxel can be increased when it is combined with Indomethacin.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Docetaxel is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Docetaxel is combined with INGN 225.Investigational
Interferon beta-1aThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1a.Approved, Investigational
Interferon beta-1bThe risk or severity of adverse effects can be increased when Docetaxel is combined with Interferon beta-1b.Approved
IobenguaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Iobenguane.Approved
IpilimumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ipilimumab.Approved
IrinotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.Approved, Investigational
IrofulvenThe risk or severity of adverse effects can be increased when Docetaxel is combined with MGI-114.Investigational
IsavuconazoniumThe metabolism of Docetaxel can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoconazoleThe metabolism of Docetaxel can be decreased when combined with Isoconazole.Approved
IsradipineThe metabolism of Docetaxel can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Docetaxel can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Docetaxel can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Docetaxel can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxabepiloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixabepilone.Approved, Investigational
IxazomibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ixazomib.Approved
KetamineThe serum concentration of Docetaxel can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Docetaxel can be decreased when combined with Ketoconazole.Approved, Investigational
KOS-1584The risk or severity of adverse effects can be increased when Docetaxel is combined with KOS-1584.Investigational
LanreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lanreotide.Approved
LansoprazoleThe serum concentration of Docetaxel can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lapatinib.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leflunomide.Approved, Investigational
LenalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenalidomide.Approved
LenvatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lenvatinib.Approved
LetrozoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Letrozole.Approved, Investigational
LeuprolideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Leuprolide.Approved, Investigational
LevofloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Levofloxacin.Approved, Investigational
LevothyroxineThe serum concentration of Docetaxel can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Docetaxel can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Docetaxel can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Docetaxel can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Docetaxel can be increased when it is combined with Lisinopril.Approved, Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomefloxacin.Approved
LomitapideThe serum concentration of Docetaxel can be increased when it is combined with Lomitapide.Approved
LomustineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Lomustine.Approved
LoperamideThe serum concentration of Docetaxel can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Docetaxel can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Docetaxel can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Docetaxel can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Docetaxel can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Docetaxel can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Docetaxel can be decreased when it is combined with Lumacaftor.Approved
MaprotilineThe serum concentration of Docetaxel can be increased when it is combined with Maprotiline.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Masoprocol.Approved
MebendazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mebendazole.Approved, Vet Approved
MechlorethamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mechlorethamine.Approved
MedrogestoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medrogestone.Approved
Medroxyprogesterone acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Medroxyprogesterone acetate.Approved, Investigational
MefloquineThe serum concentration of Docetaxel can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Megestrol acetate.Approved, Vet Approved
MelphalanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Melphalan.Approved
MeprobamateThe serum concentration of Docetaxel can be increased when it is combined with Meprobamate.Approved, Illicit
MercaptopurineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mercaptopurine.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Docetaxel.Withdrawn
MethadoneThe serum concentration of Docetaxel can be increased when it is combined with Methadone.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate.Approved
Methyl aminolevulinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyl aminolevulinate.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methylprednisolone.Approved, Vet Approved
MethyltestosteroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Methyltestosterone.Approved
MetoprololThe serum concentration of Docetaxel can be increased when it is combined with Metoprolol.Approved, Investigational
MevastatinThe metabolism of Docetaxel can be decreased when combined with Mevastatin.Experimental
MibefradilThe serum concentration of Docetaxel can be increased when it is combined with Mibefradil.Withdrawn
MicafunginThe metabolism of Docetaxel can be decreased when combined with Micafungin.Approved, Investigational
MiconazoleThe metabolism of Docetaxel can be decreased when combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Docetaxel can be decreased when it is combined with Midazolam.Approved, Illicit
MidostaurinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Docetaxel can be increased when it is combined with Mifepristone.Approved, Investigational
MiltefosineThe metabolism of Docetaxel can be decreased when combined with Miltefosine.Approved
MitomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitomycin.Approved
MitotaneThe serum concentration of Docetaxel can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Docetaxel can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Docetaxel can be increased when it is combined with Morphine.Approved, Investigational
motexafin gadoliniumThe risk or severity of adverse effects can be increased when Docetaxel is combined with motexafin gadolinium.Investigational
MoxifloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Moxifloxacin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.Approved
MyxothiazolThe metabolism of Docetaxel can be decreased when combined with Myxothiazol.Experimental
NafcillinThe serum concentration of Docetaxel can be decreased when it is combined with Nafcillin.Approved
NaftifineThe metabolism of Docetaxel can be decreased when combined with Naftifine.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nalidixic Acid.Approved
NaltrexoneThe serum concentration of Docetaxel can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Docetaxel can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.Approved, Investigational
NatamycinThe metabolism of Docetaxel can be decreased when combined with Natamycin.Approved
NecitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Necitumumab.Approved
NedaplatinNedaplatin may increase the myelosuppressive activities of Docetaxel.Approved
NefazodoneThe metabolism of Docetaxel can be decreased when combined with Nefazodone.Approved, Withdrawn
NelarabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nelarabine.Approved, Investigational
NelfinavirThe metabolism of Docetaxel can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Docetaxel can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Docetaxel can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Docetaxel can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Docetaxel can be increased when it is combined with Nicardipine.Approved
NifedipineThe serum concentration of Docetaxel can be decreased when it is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Niguldipine.Experimental
NilotinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilotinib.Approved, Investigational
NilutamideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nilutamide.Approved
NintedanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nintedanib.Approved
NisoldipineThe serum concentration of Docetaxel can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Docetaxel can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Docetaxel can be increased when it is combined with Nitrendipine.Approved
NitroxolineThe metabolism of Docetaxel can be decreased when combined with Nitroxoline.Approved
NivolumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Nivolumab.Approved
nocodazoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with nocodazole.Experimental
NorethisteroneThe serum concentration of Docetaxel can be decreased when it is combined with Norethisterone.Approved
NorfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Norfloxacin.Approved
NOV-002NOV-002 may increase the myelosuppressive activities of Docetaxel.Investigational
NystatinThe metabolism of Docetaxel can be decreased when combined with Nystatin.Approved, Vet Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Obinutuzumab.Approved
OctreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Octreotide.Approved, Investigational
OfatumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofatumumab.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ofloxacin.Approved
OlaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Docetaxel.Experimental
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Omacetaxine mepesuccinate.Approved
OmeprazoleThe serum concentration of Docetaxel can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OprelvekinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Oprelvekin.Approved, Investigational
OsimertinibThe serum concentration of Docetaxel can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Docetaxel.Approved
OxaliplatinOxaliplatin may increase the myelosuppressive activities of Docetaxel.Approved, Investigational
OxiconazoleThe metabolism of Docetaxel can be decreased when combined with Oxiconazole.Approved
P-NitrophenolThe serum concentration of Docetaxel can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Docetaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Docetaxel can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Docetaxel can be increased when it is combined with Palmitic Acid.Experimental
PamidronateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pamidronate.Approved
PanitumumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panitumumab.Approved, Investigational
PanobinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Docetaxel can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Docetaxel can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib.Approved
PefloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pefloxacin.Approved
PegaspargaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pegaspargase.Approved, Investigational
PembrolizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pembrolizumab.Approved
PemetrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pemetrexed.Approved, Investigational
PentamidineThe metabolism of Docetaxel can be decreased when combined with Pentamidine.Approved
PentobarbitalThe metabolism of Docetaxel can be increased when combined with Pentobarbital.Approved, Vet Approved
PentostatinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin.Approved, Investigational
PerindoprilThe serum concentration of Docetaxel can be increased when it is combined with Perindopril.Approved
PertuzumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pertuzumab.Approved
PhenobarbitalThe metabolism of Docetaxel can be increased when combined with Phenobarbital.Approved
Phenylacetic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Phenylacetic acid.Approved
Phenylbutyric acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sodium phenylbutyrate.Approved, Investigational
PhenytoinThe metabolism of Docetaxel can be increased when combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Docetaxel.Approved, Investigational
PimozideThe serum concentration of Docetaxel can be increased when it is combined with Pimozide.Approved
PipobromanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pipobroman.Approved
PirarubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirarubicin.Investigational
PirfenidoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirfenidone.Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirlindole.Approved
PixantroneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pixantrone.Investigational
Platelet Activating FactorThe serum concentration of Docetaxel can be decreased when it is combined with Platelet Activating Factor.Experimental
PlicamycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Plicamycin.Approved, Withdrawn
PodofiloxThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podofilox.Approved
PodophyllinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Podophyllin.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pomalidomide.Approved
PonatinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ponatinib.Approved
PorfimerThe risk or severity of adverse effects can be increased when Docetaxel is combined with Porfimer.Approved, Investigational
PosaconazoleThe metabolism of Docetaxel can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PralatrexateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pralatrexate.Approved
PravastatinThe serum concentration of Docetaxel can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Docetaxel can be increased when it is combined with Prazosin.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisone.Approved, Vet Approved
PrimidoneThe metabolism of Docetaxel can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Docetaxel can be increased when it is combined with Probenecid.Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Procarbazine.Approved
ProgesteroneThe serum concentration of Docetaxel can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Docetaxel can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Docetaxel can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Docetaxel can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Docetaxel can be increased when it is combined with Protriptyline.Approved
Purine RibosideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Purine Riboside.Experimental
PuromycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Puromycin.Experimental
QuercetinThe serum concentration of Docetaxel can be increased when it is combined with Quercetin.Experimental
QuinacrineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Quinacrine.Approved
QuinidineThe serum concentration of Docetaxel can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Docetaxel can be increased when it is combined with Quinine.Approved
RadicicolThe metabolism of Docetaxel can be decreased when combined with Radicicol.Experimental
Radium Ra 223 DichlorideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Radium Ra 223 Dichloride.Approved, Investigational
RaltitrexedThe risk or severity of adverse effects can be increased when Docetaxel is combined with Raltitrexed.Approved, Investigational
RamucirumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ramucirumab.Approved, Investigational
RanibizumabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranibizumab.Approved
RanitidineThe serum concentration of Docetaxel can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Docetaxel can be increased when it is combined with Ranolazine.Approved, Investigational
RanpirnaseThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ranpirnase.Investigational
ReboxetineThe serum concentration of Docetaxel can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Regorafenib.Approved
ReserpineThe serum concentration of Docetaxel can be decreased when it is combined with Reserpine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Resveratrol.Experimental, Investigational
Rhodamine 6GThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rhodamine 6G.Experimental
RifabutinThe metabolism of Docetaxel can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Docetaxel can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Docetaxel can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Docetaxel can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Docetaxel is combined with CDX-110.Investigational
RitonavirThe metabolism of Docetaxel can be decreased when combined with Ritonavir.Approved, Investigational
RituximabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rituximab.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Docetaxel.Approved
RolapitantThe serum concentration of Docetaxel can be increased when it is combined with Rolapitant.Approved
RomidepsinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romidepsin.Approved, Investigational
RomiplostimThe risk or severity of adverse effects can be increased when Docetaxel is combined with Romiplostim.Approved
RoquinimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Roquinimex.Investigational
RucaparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Rucaparib.Approved, Investigational
RuxolitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ruxolitinib.Approved
Salicylhydroxamic AcidThe metabolism of Docetaxel can be decreased when combined with Salicylhydroxamic Acid.Experimental
Salicylic acidThe metabolism of Docetaxel can be decreased when combined with Salicylic acid.Approved, Vet Approved
SaquinavirThe metabolism of Docetaxel can be decreased when combined with Saquinavir.Approved, Investigational
SatraplatinSatraplatin may increase the myelosuppressive activities of Docetaxel.Investigational
ScopolamineThe serum concentration of Docetaxel can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Docetaxel can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SeocalcitolThe risk or severity of adverse effects can be increased when Docetaxel is combined with Seocalcitol.Experimental
SertaconazoleThe metabolism of Docetaxel can be decreased when combined with Sertaconazole.Approved
SertralineThe serum concentration of Docetaxel can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Docetaxel can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Docetaxel can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Docetaxel can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Docetaxel can be increased when it is combined with Simvastatin.Approved
SinefunginThe metabolism of Docetaxel can be decreased when combined with Sinefungin.Experimental
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.Approved
SirolimusThe metabolism of Docetaxel can be decreased when combined with Sirolimus.Approved, Investigational
SonidegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sonidegib.Approved, Investigational
SorafenibThe serum concentration of Docetaxel can be increased when it is combined with Sorafenib.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfloxacin.Approved
Sparfosic acidThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparfosic acid.Experimental
SparsomycinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sparsomycin.Experimental
SpironolactoneThe serum concentration of Docetaxel can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Docetaxel is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Docetaxel is combined with SRT501.Investigational
St. John's WortThe serum concentration of Docetaxel can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Docetaxel can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Docetaxel can be increased when it is combined with Stiripentol.Approved
StreptozocinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Streptozocin.Approved
SulconazoleThe metabolism of Docetaxel can be decreased when combined with Sulconazole.Approved
SulfinpyrazoneThe serum concentration of Docetaxel can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Docetaxel can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sulindac.Approved
SumatriptanThe serum concentration of Docetaxel can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib.Approved, Investigational
SuraminThe risk or severity of adverse effects can be increased when Docetaxel is combined with Suramin.Approved
SwainsonineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Swainsonine.Experimental
TacrineThe serum concentration of Docetaxel can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Docetaxel.Approved, Investigational
TacrolimusThe serum concentration of Docetaxel can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Docetaxel can be increased when it is combined with Taurocholic Acid.Experimental
TavaboroleThe metabolism of Docetaxel can be decreased when combined with Tavaborole.Approved
TegafurThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tegafur.Approved
TelaprevirThe metabolism of Docetaxel can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Docetaxel can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Docetaxel can be increased when it is combined with Telmisartan.Approved, Investigational
TemafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temafloxacin.Withdrawn
TemozolomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of adverse effects can be increased when Docetaxel is combined with Temsirolimus.Approved
TeniposideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Teniposide.Approved
TerazosinThe serum concentration of Docetaxel can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Docetaxel can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerconazoleThe metabolism of Docetaxel can be decreased when combined with Terconazole.Approved
TerfenadineThe serum concentration of Docetaxel can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Docetaxel can be increased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Docetaxel can be decreased when it is combined with Tesmilifene.Investigational
TestolactoneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Testolactone.Approved
TestosteroneThe serum concentration of Docetaxel can be increased when it is combined with Testosterone.Approved, Investigational
TetrathiomolybdateThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tetrathiomolybdate.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thiotepa.Approved
ThymalfasinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Thymalfasin.Approved, Investigational
ThymolThe metabolism of Docetaxel can be decreased when combined with Thymol.Approved
TiboloneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tibolone.Approved
TicagrelorThe serum concentration of Docetaxel can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Docetaxel can be decreased when combined with Ticlopidine.Approved
TioconazoleThe metabolism of Docetaxel can be decreased when combined with Tioconazole.Approved
TioguanineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tioguanine.Approved
TipifarnibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tipifarnib.Investigational
TirapazamineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tirapazamine.Investigational
TocilizumabThe serum concentration of Docetaxel can be decreased when it is combined with Tocilizumab.Approved
TofacitinibDocetaxel may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolnaftateThe metabolism of Docetaxel can be decreased when combined with Tolnaftate.Approved, Vet Approved
TolvaptanThe serum concentration of Docetaxel can be increased when it is combined with Tolvaptan.Approved
TopotecanThe risk or severity of adverse effects can be increased when Docetaxel is combined with Topotecan.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Toremifene.Approved, Investigational
TositumomabThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tositumomab.Approved
TrabectedinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trabectedin.Approved, Investigational
TrametinibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trametinib.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Docetaxel.Approved, Investigational
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trastuzumab emtansine.Approved
TrazodoneThe serum concentration of Docetaxel can be decreased when it is combined with Trazodone.Approved, Investigational
TretazicarThe risk or severity of adverse effects can be increased when Docetaxel is combined with CB1954.Investigational
TretinoinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tretinoin.Approved, Investigational, Nutraceutical
TrifluoperazineThe serum concentration of Docetaxel can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Docetaxel can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrifluridineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trifluridine.Approved
TrilostaneThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trilostane.Approved, Investigational, Vet Approved, Withdrawn
TrimethoprimThe serum concentration of Docetaxel can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimetrexateThe metabolism of Docetaxel can be decreased when combined with Trimetrexate.Approved, Investigational
TrimipramineThe serum concentration of Docetaxel can be increased when it is combined with Trimipramine.Approved
TriptorelinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Triptorelin.Approved, Vet Approved
TroleandomycinThe serum concentration of Docetaxel can be increased when it is combined with Troleandomycin.Approved
TrovafloxacinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Trovafloxacin.Approved, Withdrawn
TroxacitabineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Troxacitabine.Investigational
TTNPBThe risk or severity of adverse effects can be increased when Docetaxel is combined with TTNPB.Experimental
TubercidinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Tubercidin.Experimental
UbenimexThe risk or severity of adverse effects can be increased when Docetaxel is combined with Ubenimex.Experimental
Uracil mustardThe risk or severity of adverse effects can be increased when Docetaxel is combined with Uracil mustard.Approved
ValrubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Valrubicin.Approved
VandetanibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vandetanib.Approved
VapreotideThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vapreotide.Approved, Investigational
VeliparibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Veliparib.Investigational
VemurafenibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Docetaxel can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Docetaxel can be decreased when combined with Verapamil.Approved
VerteporfinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Verteporfin.Approved, Investigational
VinblastineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinblastine.Approved
VincristineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vincristine.Approved, Investigational
VindesineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vindesine.Approved
VinorelbineThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vinorelbine.Approved, Investigational
VismodegibThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vismodegib.Approved
Vitamin AThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vitamin A.Approved, Nutraceutical, Vet Approved
VoriconazoleThe metabolism of Docetaxel can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatThe risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat.Approved, Investigational
ZimelidineThe serum concentration of Docetaxel can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Docetaxel can be decreased when combined with Ziprasidone.Approved
ZorubicinThe risk or severity of adverse effects can be increased when Docetaxel is combined with Zorubicin.Experimental
Food InteractionsNot Available
References
Synthesis Reference

Nicholas J. Sisti, Charles S. Swindell, “Method for docetaxel synthesis.” U.S. Patent US5688977, issued September, 1991.

US5688977
General ReferencesNot Available
External Links
ATC CodesL01CD02
AHFS Codes
  • 10:00.00
PDB EntriesNot Available
FDA labelDownload (140 KB)
MSDSDownload (100 KB)
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentCancer, Breast1
0CompletedTreatmentHead and Neck Cancers1
0RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1Active Not RecruitingOtherCarcinoma of the Prostate1
1Active Not RecruitingTreatmentAdenocarcinoma of the Prostate1
1Active Not RecruitingTreatmentAdvanced Breast Cancer1
1Active Not RecruitingTreatmentAdvanced Solid Tumors2
1Active Not RecruitingTreatmentBreast Cancer, Non-small Lung Cancer1
1Active Not RecruitingTreatmentCancer, Breast / Colon Cancer / Colon Neoplasms / Colonic Cancers / Kidney Cancer / Lung Cancers / Melanoma / Neoplasms, Breast1
1Active Not RecruitingTreatmentCancers1
1Active Not RecruitingTreatmentCarcinoma of the Prostate1
1Active Not RecruitingTreatmentNeoplasms, Breast1
1Active Not RecruitingTreatmentNeoplasms / Solid Cancers1
1Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC) / Non-Small-Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1Active Not RecruitingTreatmentTumors, Solid2
1Active Not RecruitingTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1CompletedNot AvailableGastric Cancers1
1CompletedTreatmentAdenocarcinoma of the Prostate / Advanced Solid Tumors1
1CompletedTreatmentAdvanced Neoplastic Disease1
1CompletedTreatmentAdvanced Non-Hematologic Malignancies1
1CompletedTreatmentAdvanced Solid Tumors4
1CompletedTreatmentAdvanced Solid Tumors / Non Small Cell Lung Cancer (NSCLC)1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Carcinoma of the Prostate / Carcinoma of Unknown Primary / Esophageal Cancers / Gastric Cancers / Head and Neck Cancers / Lung Cancers / Melanoma (Skin) / Pancreatic Cancers / Sarcomas1
1CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Carcinoma of the Prostate / Kidney Cancer / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentBrenner Tumor / Fallopian Tube Cancer / Ovarian Carcinosarcoma / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Mucinous Cystadenocarcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Primary Peritoneal Cavity Cancer / Stage II Ovarian Epithelial Cancer / Stage III Ovarian Epithelial Cancer / Stage IV Ovarian Epithelial Cancer1
1CompletedTreatmentCancer of Parotid / Head and Neck Cancers / Malignant Neoplasm of Thyroid / Melanoma / Parotid Gland Cancer / Stage IV Head and Neck Cancer / Thyroid Gland Cancer1
1CompletedTreatmentCancer, Advanced3
1CompletedTreatmentCancer, Breast6
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Carcinoma of the Prostate / Esophageal Cancers / Gastric Cancers / Head and Neck Cancers / Lung Cancers1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Peritoneal Cancer1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Head and Neck Cancers / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentCancer, Breast / Cancer, Ovarian / Non-Small Cell Lung / Pancreatic Cancers / Tumors, Solid1
1CompletedTreatmentCancer, Breast / Carcinoma of the Prostate / Non-Small-Cell Lung Carcinoma (NSCLC)1
1CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
1CompletedTreatmentCancer, Breast / Neutropenias1
1CompletedTreatmentCancer, Neoplasms, Tumors1
1CompletedTreatmentCancer, Ovarian1
1CompletedTreatmentCancer, Ovarian / Cervical Cancers / Endometrial Cancers / Fallopian Tube Cancer / Peritoneal Cavity Cancer / Sarcomas / Vaginal Cancers / Vulvar Cancers1
1CompletedTreatmentCancer, Ovarian / Endometrial Cancers / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancers5
1CompletedTreatmentCancers / Carcinomas1
1CompletedTreatmentCancers / Nausea and Vomiting, Chemotherapy-Induced1
1CompletedTreatmentCancers / Neoplasms / Tumors1
1CompletedTreatmentCarcinoma of the Prostate10
1CompletedTreatmentEsophageal Cancers2
1CompletedTreatmentEsophageal Squamous Cell Carcinomas1
1CompletedTreatmentFallopian Tube Carcinoma / Primary Peritoneal Carcinoma / Recurrent Ovarian Carcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
1CompletedTreatmentHEAD & NECK Cancer1
1CompletedTreatmentHER-2 Gene Amplification1
1CompletedTreatmentHead and Neck Cancers3
1CompletedTreatmentLocally Advanced, Metastatic Solid Tumors1
1CompletedTreatmentLocally Recurrent and Metastatic Breast Cancer1
1CompletedTreatmentLung Cancers1
1CompletedTreatmentMalignant Diseases1
1CompletedTreatmentMetastatic Breast Cancer (MBC)1
1CompletedTreatmentMetastatic Cancers1
1CompletedTreatmentMetastatic Melanoma1
1CompletedTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1CompletedTreatmentNeoplasms7
1CompletedTreatmentNeoplasms Malignant1
1CompletedTreatmentNeoplasms, Breast1
1CompletedTreatmentNeoplasms, Esophageal1
1CompletedTreatmentNeoplasms, Head and Neck1
1CompletedTreatmentNeoplasms, Malignant1
1CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1CompletedTreatmentOvarian Carcinoma1
1CompletedTreatmentPancreatic Cancers1
1CompletedTreatmentProstate Cancer Metastatic1
1CompletedTreatmentProstatic Neoplasms2
1CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
1CompletedTreatmentRecurrent Prostate Cancer / Stage IV Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentResistant Solid Malignancies1
1CompletedTreatmentSarcomas1
1CompletedTreatmentSolid Cancers1
1CompletedTreatmentSolid Tumor Cancers2
1CompletedTreatmentSolid Tumor Malignancies1
1CompletedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1CompletedTreatmentStomach Cancer1
1CompletedTreatmentTumors1
1CompletedTreatmentTumors, Solid5
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific17
1Not Yet RecruitingOtherAdvanced Solid Tumors, Neoplasms, Advanced Solid1
1RecruitingBasic ScienceNeoplasms1
1RecruitingBasic ScienceSoft Tissue Sarcoma Adult1
1RecruitingTreatmentAdenocarcinoma of the Pancreas / Head and Neck Squamous Cell Carcinoma (HNSCC) / Metastatic Pancreatic Adenocarcinoma / Non-Resectable Cholangiocarcinoma / Recurrent Gallbladder Carcinoma / Recurrent Non-Small Cell Lung Carcinoma / Stage III Pancreatic Cancer / Stage IIIA Gallbladder Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Gallbladder Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Gallbladder Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Pancreatic Cancer / Unresectable Gallbladder Carcinoma / Unresectable Pancreatic Cancer1
1RecruitingTreatmentAdvanced Malignancies / Cancer, Advanced1
1RecruitingTreatmentCarcinoma of the Prostate2
1RecruitingTreatmentEsophageal Squamous Cell Carcinomas1
1RecruitingTreatmentFumarate Hydratase (FH)-Deficient Tumors / Mesothelioma / Non Small Cell Lung Cancer (NSCLC) / Renal Cell Carcinoma (RCC) / Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) / Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors / Triple-Negative Breast Cancer (TNBC) / Tumors Harboring Amplifications in the cMyc Gene / Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations / Tumors, Solid1
1RecruitingTreatmentHER2 Positive Breast Cancers / HER2-negative Metastatic Breast Cancer / HER2-positive Metastatic Breast Cancer / Locally Advanced or Early Breast Cancer1
1RecruitingTreatmentHead and Neck Cancers2
1RecruitingTreatmentHead and Neck Cancers / Salivary Gland Tumors1
1RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC) / Stage III Laryngeal Squamous Cell Carcinoma / Stage III Oral Cavity Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Oral Cavity Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
1RecruitingTreatmentInflammatory carcinoma of the breast1
1RecruitingTreatmentLung Cancers1
1RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer / Prostatic Neoplasms1
1RecruitingTreatmentMetastatic Gastric Adenocarcinoma1
1RecruitingTreatmentMetastatic Triple Negative Breast Cancer1
1RecruitingTreatmentMetastatic Urothelial Carcinoma of the Renal Pelvis and Ureter / Recurrent Bladder Carcinoma / Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter / Regional Urothelial Carcinoma of the Renal Pelvis and Ureter / Stage III Bladder Urothelial Carcinoma / Stage III Urethral Cancer / Stage IV Bladder Urothelial Carcinoma / Stage IV Urethral Cancer / Urethral Urothelial Carcinoma1
1RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1RecruitingTreatmentProstate Cancer Metastatic1
1RecruitingTreatmentProstatic Neoplasms1
1RecruitingTreatmentRecurrent Non-small Cell Lung Cancer1
1RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
1SuspendedTreatmentCancers1
1SuspendedTreatmentOncology, Medical1
1TerminatedNot AvailableNon-hematologic Malignancies / Pharmacokinetics of ASP98531
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
1TerminatedTreatmentAdvanced Malignancies, Non-small Cell Lung Cancer1
1TerminatedTreatmentAdvanced Solid Tumors1
1TerminatedTreatmentBladder Cancers / Carcinoma of the Prostate / Carcinoma, Urothelial / Non-small Cell Lung, Prostate, Bladder/Urothelial Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentBreast Cancer Metastatic1
1TerminatedTreatmentCancer, Breast1
1TerminatedTreatmentCancer, Breast / Carcinoma of the Prostate / Carcinoma, Colorectal / Lung Cancers / Soft Tissue Sarcoma (STS)1
1TerminatedTreatmentCancer, Breast / Carcinoma of the Prostate / Gastric Cancers / Lung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) / Prostatic Cancer / Pulmonary Cancer / Stomach Cancer1
1TerminatedTreatmentCarcinoma of the Prostate / Prostate Cancer Metastatic Disease / Urologic Neoplasms1
1TerminatedTreatmentCervical Cancers1
1TerminatedTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Colon Cancer / Recurrent Non-small Cell Lung Cancer / Recurrent Rectal Cancer / Recurrent Small Cell Lung Cancer / Stage IV Colon Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Rectal Cancer1
1TerminatedTreatmentLung Cancers2
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNeoplasms, Advanced or Metastatic1
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1TerminatedTreatmentTumors1
1TerminatedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusTreatmentCancer, Advanced1
1Unknown StatusTreatmentCarcinoma of the Prostate2
1Unknown StatusTreatmentHNSCC1
1Unknown StatusTreatmentTumors, Solid1
1WithdrawnTreatmentCancer, Breast1
1WithdrawnTreatmentCancer, Breast / Carcinoma of the Prostate / Head and Neck Cancers / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1WithdrawnTreatmentCancer, Ovarian / Ovarian Carcinoma / Recurrent Ovarian Cancer / Recurrent Ovarian Carcinoma1
1WithdrawnTreatmentChemotherapeutic Agent Toxicity / Lung Cancers1
1WithdrawnTreatmentLung Cancer, Non-Small Cell1
1WithdrawnTreatmentProstatic Neoplasms1
1WithdrawnTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
1WithdrawnTreatmentTumors, Solid1
1, 2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
1, 2Active Not RecruitingTreatmentCarcinoma of the Prostate2
1, 2Active Not RecruitingTreatmentEsophageal Cancers1
1, 2Active Not RecruitingTreatmentGastric Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentLocally Advanced Sarcoma / Metastatic Sarcoma / Sarcomas / Soft Tissue Sarcoma (STS) / Unresectable Sarcoma1
1, 2Active Not RecruitingTreatmentMetastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Recurrent Verrucous Carcinoma of the Larynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Salivary Gland Squamous Cell Carcinoma / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IVA Oral Cavity Squamous Cell Carcinoma / Stage IVA Salivary Gland Cancer / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Salivary Gland Cancer / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Stage IVC Salivary Gland Cancer / Stage IVC Squamous Cell Carcinoma of the Larynx / Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVC Squamous Cell Carcinoma of the Oropharynx / Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IVC Verrucous Carcinoma of the Larynx / Stage IVC Verrucous Carcinoma of the Oral Cavity / Tongue Cancer / Untreated Metastatic Squamous Neck Cancer With Occult Primary1
1, 2Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
1, 2CompletedTreatmentAdult Solid Neoplasm / Inflammatory Breast Carcinoma / Male Breast Carcinoma / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer1
1, 2CompletedTreatmentAdvanced Squamous Cell Carcinoma / Squamous Cell Carcinoma of Head and Neck / SSCHN1
1, 2CompletedTreatmentBladder Cancers / Cancer, Breast / Cancer, Ovarian / Carcinoma of the Prostate / Colorectal Cancers / Esophageal Cancers / Head and Neck Cancers / Kidney Cancer / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentBone Metastases / Castration-Resistant Prostate Cancer (CRPC)1
1, 2CompletedTreatmentCancer of Head and Neck / Head and Neck Cancers / Head Cancer / Neck Cancer / Neoplasms, Neck1
1, 2CompletedTreatmentCancer of the Breast1
1, 2CompletedTreatmentCancer, Breast6
1, 2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2CompletedTreatmentCancers1
1, 2CompletedTreatmentCarcinoma of Head and/or Neck / Squamous Cell Carcinoma (SCC)1
1, 2CompletedTreatmentCarcinoma of the Prostate6
1, 2CompletedTreatmentCarcinoma of the Prostate / Metastatic, Androgen Independent Prostate Cancer1
1, 2CompletedTreatmentCarcinoma of the Prostate / Tumors1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Lymphoma NOS / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentEsophageal Cancers3
1, 2CompletedTreatmentEsophagus Cancer1
1, 2CompletedTreatmentFallopian Tube Cancer / Malignant Tumor of Peritoneum / Recurrent Ovarian Epithelial Cancer1
1, 2CompletedTreatmentGastric Cancers2
1, 2CompletedTreatmentGastrointestinal Diseases1
1, 2CompletedTreatmentHead and Neck Cancers1
1, 2CompletedTreatmentLung Cancers4
1, 2CompletedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentMetastatic Breast Cancer (MBC)2
1, 2CompletedTreatmentNeoplasms, Breast1
1, 2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
1, 2CompletedTreatmentNeoplasms, Head and Neck1
1, 2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
1, 2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
1, 2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2CompletedTreatmentOperable Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma1
1, 2CompletedTreatmentOropharynx Cancers / Squamous Cell Carcinoma of the Oral Cavity1
1, 2CompletedTreatmentProstate Cancer Metastatic1
1, 2CompletedTreatmentProstatic Neoplasms2
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Recurrent Prostate Cancer / Stage III Prostate Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer / Stage IV Prostate Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1, 2CompletedTreatmentRecurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer1
1, 2CompletedTreatmentRecurrent Salivary Gland Cancer / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Squamous Cell Carcinoma of the Larynx / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Nasopharynx / Recurrent Squamous Cell Carcinoma of the Oropharynx / Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Salivary Gland Squamous Cell Carcinoma / Stage III Salivary Gland Cancer / Stage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Salivary Gland Cancer / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IV Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Squamous Cell Carcinoma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Oropharynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity1
1, 2CompletedTreatmentStomach Neoplasms1
1, 2CompletedTreatmentTumors, Solid1
1, 2CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
1, 2RecruitingTreatmentAdvanced Solid Tumors / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentCancer, Advanced / Cancer, Breast / Ovarian / Pancreatic Cancers / Sarcomas / Small Cell Lung Cancer (SCLC)1
1, 2RecruitingTreatmentCancer, Breast / Carcinoma, Urothelial / Cholangiocarcinomas / Malignant Solid Tumours / MPN / Multiple Myeloma (MM) / Neoplasms, Endometrial / Non-Small-Cell Lung Carcinoma (NSCLC) / Stomach Neoplasms1
1, 2RecruitingTreatmentCarcinoma of the Prostate1
1, 2RecruitingTreatmentCarcinoma, Urothelial / Colorectal Adenocarcinoma (CRC) / Gastric Adenocarcinoma / Renal Cell Carcinoma (RCC)1
1, 2RecruitingTreatmentCastration Levels of Testosterone / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Prostate Carcinoma Metastatic in the Bone / PSA Progression / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
1, 2RecruitingTreatmentColorectal Cancers1
1, 2RecruitingTreatmentHead and Neck Carcinoma1
1, 2RecruitingTreatmentLocally Advanced or Metastatic Urothelial Cell Carcinoma / Urinary Bladder Diseases / Urological Diseases1
1, 2RecruitingTreatmentMetastatic Pancreatic Adenocarcinoma1
1, 2RecruitingTreatmentNeoplasms, Colorectal / Neoplasms, Gastrointestinal / Neoplasms, Pancreatic / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent / Non-Small-Cell Lung Carcinoma (NSCLC) / Progression of Non-small Cell Lung Cancer1
1, 2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2RecruitingTreatmentProstatic Neoplasms1
1, 2RecruitingTreatmentSarcomas1
1, 2RecruitingTreatmentSoft Tissue Sarcoma (STS)1
1, 2SuspendedTreatmentGastric Cancers1
1, 2TerminatedTreatmentAdenocarcinoma of the Prostate / Carcinoma of the Prostate / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage III Prostate Cancer / Stage IV Prostate Cancer1
1, 2TerminatedTreatmentAny Cancer / Cancer, Breast1
1, 2TerminatedTreatmentCancer, Breast1
1, 2TerminatedTreatmentCarcinoma of the Prostate2
1, 2TerminatedTreatmentCarcinoma of the Prostate / Pain1
1, 2TerminatedTreatmentCarcinoma of the Prostate / Prostatic Neoplasms1
1, 2TerminatedTreatmentExtensive Stage Unresectable / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentHead and Neck Cancers1
1, 2TerminatedTreatmentLung Cancers1
1, 2TerminatedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentMale Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer / Stage IV Breast Cancer1
1, 2TerminatedTreatmentMetastatic Breast Cancer (MBC)1
1, 2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1, 2TerminatedTreatmentSquamous Non-Small Cell Lung Cancer1
1, 2Unknown StatusTreatmentCancer of the Esophagus / Gastric Cardia Carcinoma1
1, 2Unknown StatusTreatmentCancer, Ovarian1
1, 2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
1, 2Unknown StatusTreatmentCarcinoma of the Prostate1
1, 2Unknown StatusTreatmentCastrate-resistant Prostate Cancer (CRPC)1
1, 2Unknown StatusTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers1
1, 2Unknown StatusTreatmentEsophageal Cancers1
1, 2Unknown StatusTreatmentGastric cancer stage IV1
1, 2Unknown StatusTreatmentHormone Refractory Prostate Cancer1
1, 2Unknown StatusTreatmentNeoplasms, Head and Neck1
1, 2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
1, 2WithdrawnTreatmentCervical Cancers1
1, 2WithdrawnTreatmentLung Cancers1
1, 2WithdrawnTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2Active Not RecruitingNot AvailableAdenocarcinoma of the Gastro-oesophageal Junction / Metastatic Gastric Cancers1
2Active Not RecruitingBasic ScienceStage II Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage I Prostate Cancer / Stage IIA Prostate Cancer / Stage IIB Prostate Cancer / Stage III Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Metastatic Prostatic Adenocarcinoma / Recurrent Prostate Carcinoma1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Gastric Cancers2
2Active Not RecruitingTreatmentAdvanced Non-Small Cell Lung Cancer1
2Active Not RecruitingTreatmentBladder Cancers / Carcinoma, Urothelial1
2Active Not RecruitingTreatmentCancer, Breast12
2Active Not RecruitingTreatmentCarcinoma of the Prostate3
2Active Not RecruitingTreatmentCarcinoma of the Prostate / Prostate Cancer Metastatic1
2Active Not RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Active Not RecruitingTreatmentChemoradiation / Neoplasms, Esophageal1
2Active Not RecruitingTreatmentEsophageal Cancers / Gastric Cancers1
2Active Not RecruitingTreatmentGastric Adenocarcinoma With Peritoneal Carcinomatosis / Siewert Type II Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis / Siewert Type III Adenocarcinoma of Esophagogastric Junction With Peritoneal Carcinomatosis1
2Active Not RecruitingTreatmentGastric Cancers2
2Active Not RecruitingTreatmentGastric Cancers / Gastroesophageal Junction Adenocarcinoma1
2Active Not RecruitingTreatmentGastric cancer stage IV1
2Active Not RecruitingTreatmentHead and Neck Cancers4
2Active Not RecruitingTreatmentHead and Neck Cancers / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Active Not RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2Active Not RecruitingTreatmentHypopharyngeal Cancer1
2Active Not RecruitingTreatmentLeiomyosarcomas1
2Active Not RecruitingTreatmentLung Cancers1
2Active Not RecruitingTreatmentMalignant Neoplasm of Female Breast1
2Active Not RecruitingTreatmentMalignant Tumor of the Breast / Neoplasms, Breast1
2Active Not RecruitingTreatmentMelanoma1
2Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
2Active Not RecruitingTreatmentNeoplasms, Breast1
2Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
2Active Not RecruitingTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
2Active Not RecruitingTreatmentPancreatic Cancers2
2Active Not RecruitingTreatmentProstate Cancer Metastatic1
2Active Not RecruitingTreatmentProstate Cancer Metastatic Castration Resistant1
2Active Not RecruitingTreatmentProstatic Neoplasms3
2Active Not RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Hypopharynx Stage III / Squamous Cell Carcinoma of the Hypopharynx Stage IV / Squamous Cell Carcinoma of the Larynx Stage III / Squamous Cell Carcinoma of the Larynx Stage IV / Squamous Cell Carcinoma of the Oral Cavity Stage III / Squamous Cell Carcinoma of the Oral Cavity Stage IV / Squamous Cell Carcinoma of the Oropharynx Stage III / Squamous Cell Carcinoma of the Oropharynx Stage IV1
2CompletedNot AvailableNon Small Cell Lung Cancer (NSCLC)1
2CompletedNot AvailableProstate Cancer Metastatic1
2CompletedPreventionCarcinoma of the Prostate1
2CompletedPreventionFebrile Neutropenia / Grade 3/4 Neutropenia1
2CompletedPreventionUnresectable Locally Advanced NSCLC1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdenocarcinoma of the Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Recurrent Esophageal Cancer / Squamous Cell Carcinoma of the Esophagus / Stage IV Esophageal Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Large Cell Lung Cancer / Malignant Pleural Effusions / Recurrent Non-small Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentAdenocarcinoma of the Lung / Non-Small-Cell Lung Cancer (NSCLC) / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Recurrent Pancreatic Cancer / Stage IV Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Pancreas / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Carcinoma of the Prostate2
2CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma of the Prostate / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
2CompletedTreatmentAdenocarcinoma, Prostate1
2CompletedTreatmentAdenocarcinomas of the Esophagogastric Junction / Gastric Cancers2
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
2CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
2CompletedTreatmentAdrenocortical Carcinoma1
2CompletedTreatmentAdvanced Breast Cancer1
2CompletedTreatmentAdvanced Endometrial Adenocarcinoma, Stage III A, B, C1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer1
2CompletedTreatmentAdvanced Non-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentAmpullary Cancer / Cholangiocarcinoma Cancer / Gallbladder Cancer / Pancreatic Cancers1
2CompletedTreatmentAnemias / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Neutropenias1
2CompletedTreatmentBRCA1 Mutation Carrier / BRCA2 Mutation Carrier / Cancer, Breast / Hereditary Breast/Ovarian Cancer (brca1, brca2)1
2CompletedTreatmentBiliary Tract Neoplasms / Neoplasms, Pancreatic1
2CompletedTreatmentBladder Cancers3
2CompletedTreatmentBladder Cancers / Cancer, Breast / Head and Neck Cancers / Lung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter / Urethral Cancer1
2CompletedTreatmentBladder Cancers / Transitional Cell Carcinoma1
2CompletedTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Sarcomas1
2CompletedTreatmentCancer of Esophagus / Cancer of the Esophagus / Esophageal Cancers / Esophagus Cancer / Neoplasms, Esophageal1
2CompletedTreatmentCancer, Breast72
2CompletedTreatmentCancer, Breast / Carcinoma of the Prostate / Lung Cancers1
2CompletedTreatmentCancer, Breast / Fevers / Neutropenias1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC)1
2CompletedTreatmentCancer, Breast / Metastatic Breast Cancer (MBC) / Tumors, Solid1
2CompletedTreatmentCancer, Breast / Neoplasms Metastasis2
2CompletedTreatmentCancer, Breast / Neoplasms, Breast1
2CompletedTreatmentCancer, Breast / Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentCancer, Ovarian4
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Malignant Tumor of Peritoneum1
2CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer3
2CompletedTreatmentCancer, Ovarian / Peritoneal Cavity Cancer3
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCancers1
2CompletedTreatmentCarcinoma of Head/Neck / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentCarcinoma of Renal Pelvis / Carcinoma of Ureter / Carcinoma of Urinary Tract / Urethral Carcinoma1
2CompletedTreatmentCarcinoma of the Prostate38
2CompletedTreatmentCarcinoma of the Prostate / Hormone Refractory / Metastatic1
2CompletedTreatmentCarcinoma of the Prostate / Metastatic Cancers3
2CompletedTreatmentCarcinoma of the Prostate / Pain1
2CompletedTreatmentCarcinoma of the Prostate / Thromboembolism1
2CompletedTreatmentCarcinomas / Nasopharyngeal Neoplasms1
2CompletedTreatmentCervical Cancers2
2CompletedTreatmentCervical Squamous Cell Carcinoma / Cervical Squamous Cell Carcinoma, Not Otherwise Specified / Recurrent Cervical Carcinoma1
2CompletedTreatmentCervix Neoplasms1
2CompletedTreatmentCervix Neoplasms / Neoplasms, Lung / Neoplasms, Ovarian / Renal Neoplasms1
2CompletedTreatmentERBB2 Gene Amplification / Neoplasms Metastasis / Stomach Neoplasms1
2CompletedTreatmentEndometrial Cancers2
2CompletedTreatmentEsophageal Adenocarcinomas / Gastric Adenocarcinoma1
2CompletedTreatmentEsophageal Cancers4
2CompletedTreatmentEsophageal Cancers / Gastric Cancers / GE Junction Cancer1
2CompletedTreatmentEsophageal Cancers / Gastric Cancers5
2CompletedTreatmentEsophageal Cancers / Stomach Cancer1
2CompletedTreatmentEsophageal Carcinoma1
2CompletedTreatmentFemale Breast Cancer1
2CompletedTreatmentGastric Adenocarcinoma1
2CompletedTreatmentGastric Cancer Adenocarcinoma Metastatic1
2CompletedTreatmentGastric Cancers8
2CompletedTreatmentGastric Cancers / Neoplasms, Esophageal1
2CompletedTreatmentGastric Cancers / Peritoneal Carcinomatosis1
2CompletedTreatmentGastric cancer stage IV1
2CompletedTreatmentGastric cancer stage IV / Gastro-esophageal Junction Cancer1
2CompletedTreatmentGastro Oesophageal Cancer1
2CompletedTreatmentHER-2 Positive Metastatic Breast Cancer1
2CompletedTreatmentHER2 Negative Breast Cancer1
2CompletedTreatmentHead and Neck Cancers16
2CompletedTreatmentHead and Neck Cancers / Squamous Cell Cancer1
2CompletedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2CompletedTreatmentHead and Neck / Head and Neck Cancers / Recurrent Disease / Squamous Cell Carcinoma (SCC)1
2CompletedTreatmentHemangiosarcoma / Histiocytoma / Leiomyosarcomas / Malignant Fibrous / Sarcomas1
2CompletedTreatmentHormone Refractory Prostate Cancer1
2CompletedTreatmentHormone Resistant Prostate Cancer / Prostate Cancer Metastatic1
2CompletedTreatmentHormone-Refractory Prostate Cancer2
2CompletedTreatmentIndividualized Chemotherapy1
2CompletedTreatmentLarynx Carcinoma / Squamous Cell Carcinoma of the Hypopharynx1
2CompletedTreatmentLeiomyosarcomas / Uterine Neoplasms1
2CompletedTreatmentLeukemias1
2CompletedTreatmentLiver Cancer1
2CompletedTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
2CompletedTreatmentLung Cancer, Non-Small Cell1
2CompletedTreatmentLung Cancer, Non-Small Cell / Non-Small-Cell Lung Cancer (NSCLC)1
2CompletedTreatmentLung Cancers30
2CompletedTreatmentLung Cancers / Non Small Cell Lung Cancer (NSCLC)1
2CompletedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentMalignant Gastrointestinal Stromal Tumor / Sarcomas1
2CompletedTreatmentMalignant Pleural Effusions / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentMalignant Solid Tumors1
2CompletedTreatmentMelanoma1
2CompletedTreatmentMetastatic Breast Cancer (MBC)10
2CompletedTreatmentMetastatic Carcinoma / Recurrent Esophageal Squamous Cell Carcinoma1
2CompletedTreatmentMetastatic Melanoma1
2CompletedTreatmentMetastatic Non-Small Cell Lung Cancer1
2CompletedTreatmentMetastatic Pancreatic Carcinoma1
2CompletedTreatmentMetastatic Soft Tissue Sarcoma1
2CompletedTreatmentMetastatic Transitional Cell Cancer of the Urothelial Tract1
2CompletedTreatmentMetastatic or Recurrent Squamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentNasopharyngeal Carcinoma1
2CompletedTreatmentNasopharyngeal Neoplasms2
2CompletedTreatmentNasopharyngeal Squamous Cell Carcinoma / Toxicity Due to Radiotherapy1
2CompletedTreatmentNeoplasms Metastasis / Stomach Neoplasms1
2CompletedTreatmentNeoplasms, Breast11
2CompletedTreatmentNeoplasms, Esophageal / Stomach Neoplasms2
2CompletedTreatmentNeoplasms, Head and Neck4
2CompletedTreatmentNeoplasms, Lung4
2CompletedTreatmentNeoplasms, Ovarian2
2CompletedTreatmentNeoplasms, Ovarian / Uterine Neoplasms1
2CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)9
2CompletedTreatmentNon-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line1
2CompletedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)31
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Recurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
2CompletedTreatmentOvarian Carcinoma / Peritoneal Neoplasms1
2CompletedTreatmentOvarian Carcinoma / Primary Peritoneal Carcinoma1
2CompletedTreatmentOvarian Clear Cell Cystadenocarcinoma / Stage III Ovarian Cancer / Stage IV Ovarian Cancer1
2CompletedTreatmentOvarian Epithelial Cancer Recurrent1
2CompletedTreatmentPancreatic Cancer Metastatic1
2CompletedTreatmentPancreatic Cancer Stage IVA1
2CompletedTreatmentPancreatic Cancers11
2CompletedTreatmentPathological Response Rate1
2CompletedTreatmentPrimary Breast Cancer1
2CompletedTreatmentProstate Cancer Metastatic2
2CompletedTreatmentProstatic Neoplasms7
2CompletedTreatmentRecurrent Breast Cancer / Stage IV Breast Cancer2
2CompletedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Carcinosarcoma1
2CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Uterine Corpus Leiomyosarcoma1
2CompletedTreatmentResected Advanced Gastric Cancer1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentSquamous Cell Carcinoma (SCC)1
2CompletedTreatmentSquamous Cell Carcinoma of Head and Neck1
2CompletedTreatmentStomach Neoplasms5
2CompletedTreatmentTherapy, Prostatic Neoplasms1
2CompletedTreatmentTumors, Solid1
2Not Yet RecruitingTreatmentAdvanced Gastric Adenocarcinoma1
2Not Yet RecruitingTreatmentCancer, Breast1
2Not Yet RecruitingTreatmentCarcinoma of the Prostate3
2Not Yet RecruitingTreatmentCancer treatment / Carcinoma of the Prostate / Castration-Resistant Prostate Cancer (CRPC) / Circulating Tumor Cells1
2Not Yet RecruitingTreatmentCarcinoma, Squamous Cell of Head and Neck1
2Not Yet RecruitingTreatmentGastric Cancers3
2Not Yet RecruitingTreatmentMetastatic Gastric Cancers1
2Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Not Yet RecruitingTreatmentTriple Negative Breast Cancer (TNBC)1
2RecruitingDiagnosticStage IIIA Non-Small Cell Lung Cancer1
2RecruitingTreatmentAdenocarcinoma of the Lung / Lung Cancers / Non-Squamous Non-Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Gastric Cancers1
2RecruitingTreatmentAdenocarcinomas / Carcinoma, Large Cell / Heregulin / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAdenocarcinomas / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentAnal Canal Carcinoma1
2RecruitingTreatmentAnterior Tongue Squamous Cell Carcinoma / Squamous Cell Carcinoma (SCC) / Tongue Neoplasms1
2RecruitingTreatmentAntineoplastic Combined Chemotherapy Protocols1
2RecruitingTreatmentBCT Rate / PCR Rate / Safety1
2RecruitingTreatmentBrenner Tumor / Malignant Ascites / Malignant Pleural Effusions / Ovarian Clear Cell Cystadenocarcinoma / Ovarian Endometrioid Adenocarcinoma / Ovarian Mixed Epithelial Carcinoma / Ovarian Serous Cystadenocarcinoma / Ovarian Undifferentiated Adenocarcinoma / Recurrent Fallopian Tube Cancer / Recurrent Ovarian Epithelial Cancer / Recurrent Ovarian Germ Cell Tumor / Recurrent Primary Peritoneal Cavity Cancer / Stage IIIA Fallopian Tube Cancer / Stage IIIA Ovarian Epithelial Cancer / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIA Primary Peritoneal Cavity Cancer / Stage IIIB Fallopian Tube Cancer / Stage IIIB Ovarian Epithelial Cancer / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIB Primary Peritoneal Cavity Cancer / Stage IIIC Fallopian Tube Cancer / Stage IIIC Ovarian Epithelial Cancer / Stage IIIC Ovarian Germ Cell Tumor / Stage IIIC Primary Peritoneal Cavity Cancer / Stage IV Fallopian Tube Cancer / Stage IV Ovarian Epithelial Cancer / Stage IV Ovarian Germ Cell Tumor / Stage IV Primary Peritoneal Cavity Cancer1
2RecruitingTreatmentCancer, Breast8
2RecruitingTreatmentCancer, Breast / Carcinoma of the Prostate / Gastric Cancers / Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
2RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
2RecruitingTreatmentCancers1
2RecruitingTreatmentCarcinoma of the Prostate4
2RecruitingTreatmentCarcinoma of the Prostate / Prostate Neoplasms / Prostatic Neoplasms1
2RecruitingTreatmentDocetaxel, Oxaliplatin and Fluorouracil1
2RecruitingTreatmentGastric Adenocarcinoma1
2RecruitingTreatmentGastric Adenocarcinoma / Gastroesophageal-junction Adenocarcinoma1
2RecruitingTreatmentGastric Cancers1
2RecruitingTreatmentHER-2 Positive Breast Cancer1
2RecruitingTreatmentHead and Neck Cancers2
2RecruitingTreatmentHead and Neck Cancers / Larynx1
2RecruitingTreatmentHead and Neck Cancers / Recurrent1
2RecruitingTreatmentHead and Neck Cancers / Salivary Gland Tumors1
2RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)2
2RecruitingTreatmentHead-and-neck Cancer / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2RecruitingTreatmentHormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Stage IV Prostate Cancer1
2RecruitingTreatmentHypopharyngeal Cancer / Oropharyngeal Cancers1
2RecruitingTreatmentKRAS Gene Mutation / Recurrent Non-Small Cell Lung Carcinoma / Stage IV Non-Small Cell Lung Cancer1
2RecruitingTreatmentLaryngeal Cancer1
2RecruitingTreatmentMetastatic Breast Cancer (MBC)1
2RecruitingTreatmentMetastatic Colorectal Adenocarcinoma1
2RecruitingTreatmentMetastatic Prostatic Adenocarcinoma1
2RecruitingTreatmentNasopharyngeal Carcinoma1
2RecruitingTreatmentNasopharyngeal Neoplasms1
2RecruitingTreatmentNeoplasms1
2RecruitingTreatmentNeoplasms, Breast1
2RecruitingTreatmentNeoplasms, Esophageal1
2RecruitingTreatmentNeoplasms, Esophageal / Stomach Neoplasms1
2RecruitingTreatmentNeoplasms, Lung1
2RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)4
2RecruitingTreatmentOsteosarcomas1
2RecruitingTreatmentParanasal Sinus Neoplasms / Squamous Cell Carcinoma (SCC)1
2RecruitingTreatmentProstatic Neoplasms2
2RecruitingTreatmentRecurrent Head and Neck Cancer1
2RecruitingTreatmentSarcomas1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentSquamous Cell Carcinoma (SCC)1
2RecruitingTreatmentSquamous Cell Lung Cancer1
2RecruitingTreatmentStage II Lymphoepithelioma of the Nasopharynx / Stage II Squamous Cell Carcinoma of the Nasopharynx / Stage III Lymphoepithelioma of the Nasopharynx / Stage III Squamous Cell Carcinoma of the Nasopharynx / Stage IV Lymphoepithelioma of the Nasopharynx / Stage IV Squamous Cell Carcinoma of the Nasopharynx1
2RecruitingTreatmentTesticular Cancer1
2RecruitingTreatmentTriple Negative Breast Neoplasms1
2RecruitingTreatmentTriple-Negative Breast Cancer (TNBC)1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2SuspendedTreatmentCarcinoma of the Prostate1
2SuspendedTreatmentHuman Papillomavirus Infections / Stage I Oropharyngeal Squamous Cell Carcinoma / Stage II Oropharyngeal Squamous Cell Carcinoma / Stage III Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma1
2SuspendedTreatmentMetastatic Non-Small Cell Lung Cancer1
2TerminatedDiagnosticCancer, Breast1
2TerminatedDiagnosticHead and Neck Cancers1
2TerminatedPreventionCarcinoma of the Prostate1
2TerminatedTreatmentAdenocarcinoma of the Prostate / Stage IV Prostate Cancer1
2TerminatedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Adenocarcinomas1
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer2
2TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Stage IIIB or IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentBiliary Cancer2
2TerminatedTreatmentBladder Cancers1
2TerminatedTreatmentCancer of Larynx1
2TerminatedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
2TerminatedTreatmentCancer, Breast14
2TerminatedTreatmentCancer, Ovarian3
2TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
2TerminatedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
2TerminatedTreatmentCancers1
2TerminatedTreatmentCarcinoma of Esophagus1
2TerminatedTreatmentCarcinoma of the Head and Neck1
2TerminatedTreatmentCarcinoma of the Prostate10
2TerminatedTreatmentDuctal Carcinoma1
2TerminatedTreatmentEarly-Stage Breast Cancer1
2TerminatedTreatmentEsophageal Cancers2
2TerminatedTreatmentGastric Adenocarcinoma2
2TerminatedTreatmentGastric Cancers3
2TerminatedTreatmentHead and Neck Cancers2
2TerminatedTreatmentHead and Neck Cancers / Squamous Carcinoma1
2TerminatedTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2TerminatedTreatmentHepatocellular Carcinomas1
2TerminatedTreatmentHormone Refractory Prostate Cancer3
2TerminatedTreatmentHuman Papilloma Virus (HPV) / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
2TerminatedTreatmentLung Cancers5
2TerminatedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentMediastinal Neoplasms1
2TerminatedTreatmentMetastatic Breast Cancer (MBC)2
2TerminatedTreatmentNeoplasms, Breast2
2TerminatedTreatmentNeoplasms, Breast / Relapsed Breast Cancer1
2TerminatedTreatmentNeoplasms, Pancreatic1
2TerminatedTreatmentNeoplasms / Neoplasms, Head and Neck1
2TerminatedTreatmentNon Small Cell Lung Cancer (NSCLC)3
2TerminatedTreatmentNon Small Cell Lung Cancer (NSCLC) / Non Squamous Cell Lung Cancer1
2TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)12
2TerminatedTreatmentOral Cancers / Squamous Cell Carcinoma (SCC)1
2TerminatedTreatmentPancreatic Cancers2
2TerminatedTreatmentPenile Cancer1
2TerminatedTreatmentProstate Cancer Metastatic1
2TerminatedTreatmentProstatic Neoplasms3
2TerminatedTreatmentRecurrent Bladder Cancer / Stage III Bladder Cancer / Stage IV Bladder Cancer / Transitional Cell Carcinoma of the Bladder1
2TerminatedTreatmentRecurrent Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
2TerminatedTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
2Unknown StatusBasic ScienceHormone Refractory Prostate Cancer1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusSupportive CareSarcomas1
2Unknown StatusTreatmentBiliary Tract Cancer1
2Unknown StatusTreatmentBladder Cancers / Transitional Cell Cancer of the Renal Pelvis and Ureter1
2Unknown StatusTreatmentBreast Cancer Stage II / Breast Cancer Stage III1
2Unknown StatusTreatmentBreast Diseases / Cancer, Breast / Neoplasms / Neoplasms by Site1
2Unknown StatusTreatmentCancer, Breast12
2Unknown StatusTreatmentCancer, Ovarian / Endometrial Cancers / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
2Unknown StatusTreatmentCarcinoma of the Prostate4
2Unknown StatusTreatmentCarcinoma of the Prostate / Pain1
2Unknown StatusTreatmentCarcinoma, Large Cell / Non-Small-Cell Lung Carcinoma (NSCLC) / Squamous Carcinoma1
2Unknown StatusTreatmentDrug Therapy / Genes, EGFR / Neoplasms, Lung / Non-Small Cell Lung Carcinoma (NSCLC)1
2Unknown StatusTreatmentEndometrial Cancers1
2Unknown StatusTreatmentEsophageal Cancers / Gastric Cancers1
2Unknown StatusTreatmentGastric Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2Unknown StatusTreatmentGastric Cancers3
2Unknown StatusTreatmentGastric Cancers / Gastroesophageal Junction Cancer1
2Unknown StatusTreatmentGastric Cancers / Unresectable1
2Unknown StatusTreatmentGastric Junction Adenocarcinoma / Gastroesophageal Junction Adenocarcinoma1
2Unknown StatusTreatmentHead and Neck Cancers2
2Unknown StatusTreatmentLung Cancers8
2Unknown StatusTreatmentMetastatic Breast Cancer (MBC) / Recurrent Breast Cancer1
2Unknown StatusTreatmentNasopharyngeal Cancers1
2Unknown StatusTreatmentNasopharyngeal Carcinoma4
2Unknown StatusTreatmentNeoplasms, Breast1
2Unknown StatusTreatmentNon Small Cell Lung Cancer (NSCLC)4
2Unknown StatusTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)8
2Unknown StatusTreatmentPancreas Neoplasms1
2Unknown StatusTreatmentPancreatic Cancers1
2Unknown StatusTreatmentProstatic Neoplasms1
2Unknown StatusTreatmentSarcomas1
2Unknown StatusTreatmentSmall Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentSoft Tissue Sarcoma (STS)1
2Unknown StatusTreatmentSquamous Cell Carcinoma of the Head / Squamous Cell Carcinoma of the Neck1
2Unknown StatusTreatmentSquamous Cell Lung Cancer1
2Unknown StatusTreatmentStomach Cancer1
2Unknown StatusTreatmentStomach Neoplasms3
2WithdrawnTreatmentAdenocarcinoma of the Prostate / Carcinoma of the Prostate / Stage I Prostate Cancer / Stage II Prostate Cancer1
2WithdrawnTreatmentCancer, Breast6
2WithdrawnTreatmentCarcinoma of Unknown Primary1
2WithdrawnTreatmentCarcinoma of the Prostate3
2WithdrawnTreatmentCarcinoma, Urothelial2
2WithdrawnTreatmentHead and Neck Cancers1
2WithdrawnTreatmentNeoplasms, Breast2
2WithdrawnTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
2WithdrawnTreatmentSmall Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentStage IV Non-Small Cell Lung Cancer1
2WithdrawnTreatmentTumors, Solid1
2, 3Active Not RecruitingTreatmentGastric Cancers1
2, 3Active Not RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)1
2, 3Active Not RecruitingTreatmentNon-Small Cell Lung Cancer Recurrent / Non-Small-Cell Lung Carcinoma (NSCLC) / Progression of Non-small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentStage III Squamous Cell Carcinoma of the Hypopharynx / Stage III Squamous Cell Carcinoma of the Larynx / Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage III Squamous Cell Carcinoma of the Oropharynx / Stage III Verrucous Carcinoma of the Larynx / Stage III Verrucous Carcinoma of the Oral Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Stage IVA Squamous Cell Carcinoma of the Larynx / Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVA Squamous Cell Carcinoma of the Oropharynx / Stage IVA Verrucous Carcinoma of the Larynx / Stage IVA Verrucous Carcinoma of the Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Larynx / Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IVB Squamous Cell Carcinoma of the Oropharynx / Stage IVB Verrucous Carcinoma of the Larynx / Stage IVB Verrucous Carcinoma of the Oral Cavity / Tongue Cancer1
2, 3CompletedSupportive CareChemotherapy-Induced Neutropenia1
2, 3CompletedTreatmentCisplatin Adverse Reaction / Upper GI Cancer1
2, 3CompletedTreatmentNeoplasm Recurrence, Local / Neoplasms Metastasis / Neoplasms, Head and Neck1
2, 3Not Yet RecruitingNot AvailableNasopharyngeal Carcinoma1
2, 3Not Yet RecruitingTreatmentHead and Neck Squamous Cell Carcinoma (HNSCC)1
2, 3Not Yet RecruitingTreatmentStage III Breast Cancer1
2, 3RecruitingScreeningNon-Small-Cell Lung Carcinoma (NSCLC)1
2, 3RecruitingTreatmentActivating EGFR Mutation / Non-Small-Cell Lung Carcinoma (NSCLC) / Non-squamous Non-small Cell Lung Cancer Stage II / Non-squamous Non-small Cell Lung Cancer Stage IIIA / Non-squamous Non-small Cell Lung Cancer Stage IIIB1
2, 3RecruitingTreatmentCancer, Breast1
2, 3RecruitingTreatmentCancer, Breast / Triple Negative Breast Cancer (TNBC)1
2, 3RecruitingTreatmentCarcinoma of the Prostate1
2, 3RecruitingTreatmentGastric Carcinoma1
2, 3RecruitingTreatmentGastroesophageal Junction Cancer / Stomach Cancer1
2, 3RecruitingTreatmentProgression Free Survival1
2, 3RecruitingTreatmentRecurrent Squamous Cell Lung Carcinoma / Stage IV Squamous Cell Lung Carcinoma1
2, 3RecruitingTreatmentStage I Prostate Adenocarcinoma / Stage II Prostate Adenocarcinoma / Stage III Prostate Adenocarcinoma1
2, 3SuspendedTreatmentMetastatic Breast Cancer (MBC)1
2, 3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer / Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB1
2, 3TerminatedTreatmentCarcinoma of the Prostate1
2, 3Unknown StatusTreatmentCarcinoma of the Prostate1
2, 3Unknown StatusTreatmentLobaplatin and Gemcitabine in Combination, Second-line Treatments on Advanced Osteosarcoma1
2, 3Unknown StatusTreatmentLung Cancers1
2, 3Unknown StatusTreatmentPancreatic Cancer Stage II / Pancreatic Cancer Stage III1
3Active Not RecruitingNot AvailableCancer, Breast1
3Active Not RecruitingPreventionNon-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers1
3Active Not RecruitingTreatmentAnaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer / Non-Small-Cell Lung Carcinoma (NSCLC)1
3Active Not RecruitingTreatmentBladder Cancers1
3Active Not RecruitingTreatmentBreast Cancer Female1
3Active Not RecruitingTreatmentCancer, Breast20
3Active Not RecruitingTreatmentCancer, Breast / Neoplasms, Breast1
3Active Not RecruitingTreatmentCarcinoma of the Prostate6
3Active Not RecruitingTreatmentCarcinoma, Urothelial1
3Active Not RecruitingTreatmentEstrogen Receptor Negative / Estrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Negative / Progesterone Receptor Positive / Recurrent Breast Carcinoma / Stage IA Breast Cancer / Stage IB Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentEstrogen Receptor Positive / HER2/Neu Positive / Progesterone Receptor Positive / Stage IB Breast Cancer / Stage II Breast Cancer / Stage IIA Breast Cancer / Stage IIB Breast Cancer / Stage IIIA Breast Cancer / Stage IIIB Breast Cancer / Stage IIIC Breast Cancer1
3Active Not RecruitingTreatmentGastric Cancers1
3Active Not RecruitingTreatmentHead and Neck Squamous Cell Cancer1
3Active Not RecruitingTreatmentHer2 Non-overexpressing / Primary Breast Cancer1
3Active Not RecruitingTreatmentLocally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV1
3Active Not RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3Active Not RecruitingTreatmentMetastatic Castration Resistant Prostate Cancer1
3Active Not RecruitingTreatmentMetastatic Hormone-sensitive Prostate Cancer1
3Active Not RecruitingTreatmentMetastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma1
3Active Not RecruitingTreatmentNasopharyngeal Carcinoma1
3Active Not RecruitingTreatmentNeoplasms, Head and Neck1
3Active Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
3Active Not RecruitingTreatmentNon-Squamous Cell Non-small Cell Lung Cancer1
3Active Not RecruitingTreatmentNon-Squamous Non-Small Cell Lung Cancer2
3Active Not RecruitingTreatmentRecurrent Hypopharyngeal Squamous Cell Carcinoma / Recurrent Laryngeal Squamous Cell Carcinoma / Recurrent Laryngeal Verrucous Carcinoma / Recurrent Lip and Oral Cavity Squamous Cell Carcinoma / Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary / Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Recurrent Oral Cavity Verrucous Carcinoma / Recurrent Oropharyngeal Squamous Cell Carcinoma / Recurrent Salivary Gland Carcinoma / Salivary Gland Squamous Cell Carcinoma / Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary / Stage IV Hypopharyngeal Squamous Cell Carcinoma / Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IV Major Salivary Gland Cancer AJCC v7 / Stage IV Major Salivary Gland Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma / Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVA Laryngeal Verrucous Carcinoma / Stage IVA Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVA Major Salivary Gland Cancer AJCC v7 / Stage IVA Major Salivary Gland Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVA Oral Cavity Verrucous Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma / Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Squamous Cell Carcinoma / Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVB Laryngeal Verrucous Carcinoma / Stage IVB Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVB Major Salivary Gland Cancer AJCC v7 / Stage IVB Major Salivary Gland Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVB Oral Cavity Verrucous Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma / Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Squamous Cell Carcinoma / Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7 / Stage IVC Laryngeal Verrucous Carcinoma / Stage IVC Laryngeal Verrucous Carcinoma AJCC v7 / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma / Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 / Stage IVC Major Salivary Gland Cancer AJCC v7 / Stage IVC Major Salivary Gland Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma / Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7 / Stage IVC Oral Cavity Verrucous Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma / Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7 / Tongue Carcinoma / Untreated Metastatic Squamous Cell Carcinoma to Neck With Occult Primary1
3Active Not RecruitingTreatmentSquamous Cell Carcinoma of the Head and Neck (SCCHN)1
3Active Not RecruitingTreatmentSquamous Cell Non-small Cell Lung Cancer1
3Active Not RecruitingTreatmentStage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non-Small Cell Lung Cancer1
3Active Not RecruitingTreatmentUrothelial Cancer1
3CompletedNot AvailableEsophageal Cancers1
3CompletedNot AvailableNon-Small-Cell Lung Carcinoma (NSCLC)1
3CompletedPreventionCancers1
3CompletedPreventionNon Small Cell Lung Carcinoma (NSCLC)1
3CompletedSupportive CareAnorexia / Cachexia / Lethargy / Lung Cancers1
3CompletedSupportive CareCancer, Breast1
3CompletedSupportive CareCancer, Breast / Chemotherapy-Induced Neutropenia1
3CompletedSupportive CareChemotherapy-Induced Neutropenia1
3CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
3CompletedTreatmentAdenocarcinoma of the Prostate / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Stage IV Prostate Cancer1
3CompletedTreatmentAdenocarcinoma of the Stomach / Adenocarcinomas of the Gastroesophageal Junction1
3CompletedTreatmentAdenocarcinomas of the Gastroesophageal Junction / Esophageal Cancers / Gastric Cancers / Nausea and Vomiting / Pain1
3CompletedTreatmentBreast Cancer Stage I1
3CompletedTreatmentCancer of the Breast / Cancer, Breast / Neoplasms, Breast1
3CompletedTreatmentCancer, Breast36
3CompletedTreatmentCancer, Breast / Stage IV Breast Cancer1
3CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Peritoneal Cavity Cancer1
3CompletedTreatmentCancer, Ovarian / Primary Peritoneal Cavity Cancer1
3CompletedTreatmentCancers1
3CompletedTreatmentCarcinoma of the Prostate7
3CompletedTreatmentCarcinoma of the Prostate / Metastatic Cancers1
3CompletedTreatmentCarcinomas / Non Small Cell Lung1
3CompletedTreatmentGastric Cancers1
3CompletedTreatmentHead and Neck Cancers2
3CompletedTreatmentHypopharynx Cancer / Larynx Cancer1
3CompletedTreatmentIll-defined Sites / Supportive1
3CompletedTreatmentInflammatory carcinoma of the breast1
3CompletedTreatmentInoperable Gastric Cancer1
3CompletedTreatmentLung Cancers5
3CompletedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
3CompletedTreatmentMetastatic Breast Cancer (MBC)2
3CompletedTreatmentNeoplasms Metastasis / Prostatic Neoplasms1
3CompletedTreatmentNeoplasms, Breast6
3CompletedTreatmentNeoplasms, Lung2
3CompletedTreatmentNon Small Cell Lung Cancer (NSCLC)3
3CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3CompletedTreatmentNon-Small-Cell Lung Cancer Metastatic / Non-Small-Cell Lung Cancer Stage IIIB / Non-Small-Cell Lung Cancer Stage IV / Non-Small-Cell Lung Carcinoma (NSCLC) / Nonsmall Cell Lung Cancer1
3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)14
3CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
3CompletedTreatmentProstatic Neoplasms2
3CompletedTreatmentRecurrent Uterine Corpus Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
3CompletedTreatmentSoft Tissue Sarcoma (STS)1
3CompletedTreatmentSquamous Cell Carcinoma (SCC)1
3CompletedTreatmentStomach Neoplasms1
3Enrolling by InvitationTreatmentCancers1
3Enrolling by InvitationTreatmentGastric Cancers1
3Not Yet RecruitingTreatmentBreastcancer / Neutropenias1
3Not Yet RecruitingTreatmentHER2 Positive Breast Cancers1
3Not Yet RecruitingTreatmentNasopharyngeal Carcinoma2
3Not Yet RecruitingTreatmentNon-squamous Cell NSCLC1
3RecruitingNot AvailableMetastatic Castration Resistant Prostate Cancer1
3RecruitingTreatmentAdenocarcinoma, Mucinous / Carcinoma, Undifferentiated / Clear Cell Adenocarcinoma / Fallopian Tube Clear Cell Adenocarcinoma / Fallopian Tube Endometrioid Adenocarcinoma / Fallopian Tube Mucinous Adenocarcinoma / Fallopian Tube Serous Adenocarcinoma / Malignant Ovarian Mixed Epithelial Tumor / Ovarian Brenner Tumor / Ovarian Clear Cell Adenocarcinofibroma / Ovarian Endometrioid Adenocarcinoma / Ovarian Seromucinous Carcinoma / Ovarian Serous Adenocarcinoma / Primary Peritoneal Serous Adenocarcinoma / Recurrent Fallopian Tube Carcinoma / Recurrent Ovarian Carcinoma / Recurrent Primary Peritoneal Carcinoma / Undifferentiated Fallopian Tube Carcinoma / Undifferentiated Ovarian Carcinoma1
3RecruitingTreatmentAdenocarcinomas of the Esophagogastric Junction / Esophageal Adenocarcinoma (UICC TNM7)1
3RecruitingTreatmentBreast Cancer Model / Cancer, Breast / Effects of Chemotherapy1
3RecruitingTreatmentCancer, Breast5
3RecruitingTreatmentCancer, Breast / Metastasis1
3RecruitingTreatmentCervical Cancers1
3RecruitingTreatmentChemoradiotherapy / Enteral Nutrition Therapy / Esophageal Squamous Cell Carcinomas1
3RecruitingTreatmentChemotherapeutic Toxicity / Chemotherapy Effect / Stomach Neoplasms1
3RecruitingTreatmentChemotherapy Effects / Esophagus Cancer1
3RecruitingTreatmentEsophageal Cancers1
3RecruitingTreatmentEsophageal Cancers / Esophageal Squamous Cell Carcinomas / Oesophageal Cancer1
3RecruitingTreatmentEsophageal Carcinoma / Esophagogastric Junction Carcinoma1
3RecruitingTreatmentGastric Adenocarcinoma1
3RecruitingTreatmentGastric Cancer, Adjuvant Chemotherapy, XO1
3RecruitingTreatmentGastric Cancers1
3RecruitingTreatmentHER2-positive Locally Advanced or Metastatic Breast Cancer1
3RecruitingTreatmentLocally Advanced Nasopharyngeal Carcinoma1
3RecruitingTreatmentLocally Advanced Unresectable Gastric Cancer / Metastatic Gastric Cancers1
3RecruitingTreatmentMetastatic Breast Cancer (MBC)1
3RecruitingTreatmentMetastatic Castrate Resistant Prostate Cancer1
3RecruitingTreatmentNasopharyngeal Carcinoma3
3RecruitingTreatmentNon Small Cell Lung Cancer (NSCLC)2
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)6
3RecruitingTreatmentOESOPHAGO-GASTRIC CARCINOMA1
3RecruitingTreatmentOligo-metastatic Stage IV Non-small Cell Lung Cancer / Oligo-metastatic Stage IV Non-small Cell Lung Cancer(NSCLC)1
3RecruitingTreatmentOropharynx Cancers1
3RecruitingTreatmentProstate Cancer Adenocarcinoma Metastatic1
3RecruitingTreatmentProstatic Neoplasms1
3RecruitingTreatmentStage I Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer1
3TerminatedTreatmentAdvanced Non-Small Cell Lung Cancer / Metastatic Non-Small Cell Lung Cancer / Non-Small Cell Lung Cancer Stage IIIB / Non-Small-Cell Lung Adenocarcinoma1
3TerminatedTreatmentCancer, Breast3
3TerminatedTreatmentCarcinoma of the Prostate5
3TerminatedTreatmentCastrate-resistant Prostate Cancer (CRPC) / Hormone Refractory Prostate Cancer1
3TerminatedTreatmentHead and Neck Cancers2
3TerminatedTreatmentLung Cancers2
3TerminatedTreatmentMetastatic Head and Neck Cancer / Recurrent Head and Neck Cancer1
3TerminatedTreatmentNon Small Cell Lung Carcinoma (NSCLC)1
3TerminatedTreatmentNon-Small Cell Lung Carcinoma (NSCLC)2
3TerminatedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
3TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
3TerminatedTreatmentProstatic Neoplasms2
3Unknown StatusDiagnosticCancer, Breast1
3Unknown StatusScreeningNeoplasms, Lung1
3Unknown StatusTreatmentAdenocarcinoma of the Prostate1
3Unknown StatusTreatmentAdvanced Prostate Cancer1
3Unknown StatusTreatmentCancer of the Larynx / Cancer of the Nasal Cavity / Cancer of the Oral Cavity / Cancer of the Pharynx / Paranasal Sinus Neoplasms1
3Unknown StatusTreatmentCancer, Breast7
3Unknown StatusTreatmentCancer, Breast / Cardiac Toxicity / Perioperative/Postoperative Complications1
3Unknown StatusTreatmentCancer treatment / Cancer, Breast1
3Unknown StatusTreatmentCarcinoma of the Prostate3
3Unknown StatusTreatmentCarcinoma of the Prostate / Pain1
3Unknown StatusTreatmentLung Cancers3
3Unknown StatusTreatmentNon Small Cell Lung Cancer (NSCLC)1
3WithdrawnTreatmentAdult Solid Tumor / Cancer, Breast / Head and Neck Cancers / Kidney and Urinary Cancer / Male Reproductive Cancer / Thorax and Respiratory Cancer1
4Active Not RecruitingTreatmentCancer, Breast1
4Active Not RecruitingTreatmentNeoplasms, Therapy-Associated1
4CompletedNot AvailableNonsmall Cell Lung Cancer / Squamous Cell Carcinoma of the Head and Neck (SCCHN)1
4CompletedTreatmentCancer, Breast2
4CompletedTreatmentNeoplasms, Head and Neck1
4CompletedTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
4CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
4CompletedTreatmentProstatic Neoplasms1
4CompletedTreatmentSquamous Cell Carcinoma (SCC)1
4RecruitingScreeningLiver Injury, Drug-Induced1
4RecruitingTreatmentAdenocarcinomas / EGFR Positive Non-small Cell Lung Cancer1
4RecruitingTreatmentAdvanced Lung Squamous Carcinoma1
4RecruitingTreatmentCancer, Breast4
4RecruitingTreatmentNeoplasms, Breast1
4RecruitingTreatmentNon-Small-Cell Lung Cancer (NSCLC)1
4RecruitingTreatmentPatients With Head and Neck Cancer (ORL)1
4TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
4WithdrawnTreatmentCancer, Breast1
Not AvailableActive Not RecruitingNot AvailableCancer, Breast / Chemotherapeutic Agent Toxicity / Cognitive/Functional Effects / Lethargy / Long-Term Effects Secondary to Cancer Therapy in Adults / Neurotoxicity / Psychosocial Effects of Cancer and Its Treatment1
Not AvailableActive Not RecruitingNot AvailableCarcinoma of the Prostate / Metastatic Cancers1
Not AvailableActive Not RecruitingNot AvailableMalnutrition / Nasopharyngeal Carcinoma1
Not AvailableActive Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
Not AvailableActive Not RecruitingTreatmentLung Cancers1
Not AvailableCompletedNot AvailableAssociations Between Genetic Data and Docetaxel Toxicity / CYP3A Phenotyping / CYP3A5 and MDR1 Genotyping / Docetaxel Toxicity1
Not AvailableCompletedNot AvailableCancer, Breast2
Not AvailableCompletedNot AvailableCarcinoma of the Prostate / Metastatic Cancers1
Not AvailableCompletedNot AvailableColon Cancer / Metastatic Breast Cancer (MBC) / Metastatic Breast Cancer, Colon Cancer1
Not AvailableCompletedNot AvailableNeoplasms1
Not AvailableCompletedNot AvailableNeoplasms, Ovarian1
Not AvailableCompletedDiagnosticCancer, Breast1
Not AvailableCompletedHealth Services ResearchNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentCancer, Breast5
Not AvailableCompletedTreatmentHypermethylation / Lung Cancers / Non Small Cell Lung Carcinoma (NSCLC)1
Not AvailableCompletedTreatmentNon Small Cell Lung Cancer (NSCLC)1
Not AvailableRecruitingNot AvailableCarcinoma of the Prostate2
Not AvailableRecruitingHealth Services ResearchCancer, Breast1
Not AvailableRecruitingTreatmentAdenocarcinomas1
Not AvailableRecruitingTreatmentBreast Cancer Nos Premenopausal1
Not AvailableRecruitingTreatmentCastration Levels of Testosterone / Hormone-Resistant Prostate Cancer / Metastatic Prostate Carcinoma / Prostate Carcinoma Metastatic in the Bone / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
Not AvailableRecruitingTreatmentEsophageal Cancers / Gastric Cancers1
Not AvailableRecruitingTreatmentNasopharyngeal Neoplasms1
Not AvailableTerminatedTreatmentPancreatic Cancers1
Not AvailableTerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer1
Not AvailableUnknown StatusNot AvailableCarcinoma of the Prostate1
Not AvailableUnknown StatusNot AvailableHormone Refractory Prostate Cancer1
Not AvailableUnknown StatusTreatmentCancer, Breast1
Not AvailableUnknown StatusTreatmentCarcinoma of the Prostate1
Not AvailableUnknown StatusTreatmentStage IA Uterine Sarcoma / Stage IB Uterine Sarcoma / Stage IC Uterine Sarcoma / Stage IIA Uterine Sarcoma / Stage IIB Uterine Sarcoma / Stage IIIA Uterine Sarcoma / Stage IIIB Uterine Sarcoma / Stage IIIC Uterine Sarcoma / Stage IVA Uterine Sarcoma / Stage IVB Uterine Sarcoma / Uterine Corpus Leiomyosarcoma1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Kit
Injection, solutionIntravenous10 mg/mL
Injection, solutionIntravenous20 mg/mL
Injection, solutionIntravenous80 mg/4mL
Injection, solution, concentrateIntravenous20 mg/mL
Injection, solution, concentrateIntravenous20 mg/2mL
Injection, solution, concentrateIntravenous200 mg/20mL
Injection, solution, concentrateIntravenous40 mg/mL
Injection, solution, concentrateIntravenous80 mg/8mL
Injection, solution, concentrateIntravenous80 mg/4mL
SolutionIntravenous20 mg/mL
SolutionIntravenous10 mg
Injection, solution, concentrateIntravenous120 mg/6ml
Injection, solution, concentrateIntravenous160 mg/8ml
Injection, solution, concentrateIntravenous180 mg/9ml
Injection, solution, concentrateIntravenous20 mg/1ml
Injection, solution, concentrateIntravenous200 mg/10ml
InjectionIntravenous20 mg/mL
Injection, solution, concentrateIntravenous20 mg
Injection, solution, concentrateIntravenous80 mg
Kit; solutionIntravenous20 mg
Kit; solutionIntravenous80 mg
Injection, solution, concentrateIntravenous140 mg/7ml
Injection, solution, concentrateIntravenous20 mg/0.5ml
Injection, solution, concentrateIntravenous80 mg/2ml
SolutionIntravenous20 mg
SolutionIntravenous80 mg
Prices
Unit descriptionCostUnit
Taxotere 20 mg/0.5 ml vial477.37USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2149055 No2003-01-072013-11-08Canada
CA2150576 No2005-06-212013-11-26Canada
US4814470 No1993-05-142010-05-14Us
US5438072 No1994-05-222014-05-22Us
US8940786 No2013-09-302033-09-30Us
US9308195 No2013-09-302033-09-30Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point (°C)232 °CPhysProp
water solubilityInsoluble FDA label
logP2.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0127 mg/mLALOGPS
logP2.59ALOGPS
logP2.92ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)10.96ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count10ChemAxon
Hydrogen Donor Count5ChemAxon
Polar Surface Area224.45 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity203.9 m3·mol-1ChemAxon
Polarizability82.06 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9743
Blood Brain Barrier-0.9659
Caco-2 permeable-0.8252
P-glycoprotein substrateSubstrate0.8259
P-glycoprotein inhibitor IInhibitor0.644
P-glycoprotein inhibitor IINon-inhibitor0.5139
Renal organic cation transporterNon-inhibitor0.9393
CYP450 2C9 substrateNon-substrate0.816
CYP450 2D6 substrateNon-substrate0.8828
CYP450 3A4 substrateSubstrate0.7119
CYP450 1A2 substrateNon-inhibitor0.8299
CYP450 2C9 inhibitorNon-inhibitor0.8737
CYP450 2D6 inhibitorNon-inhibitor0.8972
CYP450 2C19 inhibitorNon-inhibitor0.8421
CYP450 3A4 inhibitorNon-inhibitor0.7324
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8776
Ames testNon AMES toxic0.8382
CarcinogenicityNon-carcinogens0.9133
BiodegradationNot ready biodegradable0.9934
Rat acute toxicity2.5741 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9907
hERG inhibition (predictor II)Non-inhibitor0.7905
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as taxanes and derivatives. These are diterpenoids with a structure based either on the taxane skeleton, or a derivative thereof. In term of phytochemistry, several derivatives of the taxane skeleton exist: 2(3->20)-abeotaxane, 3,11-cyclotaxane, 11(15->1),11(10->9)-abeotaxane, 3,8-seco-taxane, and 11(15->1)-abeotaxane, among others. More complex skeletons have been found recently, which include the taxane-derived [3.3.3] propellane ring system.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassPrenol lipids
Sub ClassDiterpenoids
Direct ParentTaxanes and derivatives
Alternative Parents
Substituents
  • Taxane diterpenoid
  • Benzoate ester
  • Benzoic acid or derivatives
  • Tricarboxylic acid or derivatives
  • Benzoyl
  • Fatty acid ester
  • Monocyclic benzene moiety
  • Fatty acyl
  • Monosaccharide
  • Benzenoid
  • Cyclic alcohol
  • Carbamic acid ester
  • Tertiary alcohol
  • Carboxylic acid ester
  • Ketone
  • Carbonic acid derivative
  • Oxetane
  • Secondary alcohol
  • Organoheterocyclic compound
  • Oxacycle
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Polyol
  • Organic nitrogen compound
  • Hydrocarbon derivative
  • Alcohol
  • Carbonyl group
  • Organic oxide
  • Organonitrogen compound
  • Organooxygen compound
  • Organic oxygen compound
  • Organopnictogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain (By similarity).
Gene Name:
TUBB1
Uniprot ID:
Q9H4B7
Molecular Weight:
50326.56 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985 ]
  2. Matesanz R, Barasoain I, Yang CG, Wang L, Li X, de Ines C, Coderch C, Gago F, Barbero JJ, Andreu JM, Fang WS, Diaz JF: Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem Biol. 2008 Jun;15(6):573-85. doi: 10.1016/j.chembiol.2008.05.008. [PubMed:18559268 ]
  3. Snyder JP, Nettles JH, Cornett B, Downing KH, Nogales E: The binding conformation of Taxol in beta-tubulin: a model based on electron crystallographic density. Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5312-6. Epub 2001 Apr 17. [PubMed:11309480 ]
  4. Belani CP, Eckardt J: Development of docetaxel in advanced non-small-cell lung cancer. Lung Cancer. 2004 Dec;46 Suppl 2:S3-11. [PubMed:15698529 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Ubiquitin protein ligase binding
Specific Function:
Suppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating f...
Gene Name:
BCL2
Uniprot ID:
P10415
Molecular Weight:
26265.66 Da
References
  1. Gligorov J, Lotz JP: Preclinical pharmacology of the taxanes: implications of the differences. Oncologist. 2004;9 Suppl 2:3-8. [PubMed:15161985 ]
  2. Marshall J, Chen H, Yang D, Figueira M, Bouker KB, Ling Y, Lippman M, Frankel SR, Hayes DF: A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol. 2004 Aug;15(8):1274-83. [PubMed:15277270 ]
  3. Inoue Y, Gika M, Abiko T, Oyama T, Saitoh Y, Yamazaki H, Nakamura M, Abe Y, Kawamura M, Kobayashi K: Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer. Oncol Rep. 2005 Feb;13(2):259-64. [PubMed:15643508 ]
  4. Petrylak DP: Chemotherapy for androgen-independent prostate cancer. World J Urol. 2005 Feb;23(1):10-3. Epub 2005 Feb 1. [PubMed:15685445 ]
  5. Miyoshi Y, Uemura H, Kubota Y: [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel]. Nihon Rinsho. 2005 Feb;63(2):298-302. [PubMed:15714982 ]
  6. Magi-Galluzzi C, Zhou M, Reuther AM, Dreicer R, Klein EA: Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer. 2007 Sep 15;110(6):1248-54. [PubMed:17674353 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules.
Gene Name:
MAP2
Uniprot ID:
P11137
Molecular Weight:
199524.51 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural molecule activity
Specific Function:
Non-neuronal microtubule-associated protein. Promotes microtubule assembly.
Gene Name:
MAP4
Uniprot ID:
P27816
Molecular Weight:
121003.805 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Structural constituent of cytoskeleton
Specific Function:
Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the ce...
Gene Name:
MAPT
Uniprot ID:
P10636
Molecular Weight:
78927.025 Da
References
  1. McGrogan BT, Gilmartin B, Carney DN, McCann A: Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta. 2008 Apr;1785(2):96-132. Epub 2007 Nov 12. [PubMed:18068131 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Zinc ion binding
Specific Function:
Nuclear receptor that binds and is activated by variety of endogenous and xenobiotic compounds. Transcription factor that activates the transcription of multiple genes involved in the metabolism and secretion of potentially harmful xenobiotics, drugs and endogenous compounds. Activated by the antibiotic rifampicin and various plant metabolites, such as hyperforin, guggulipid, colupulone, and is...
Gene Name:
NR1I2
Uniprot ID:
O75469
Molecular Weight:
49761.245 Da
References
  1. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, Taguchi H, Koeffler HP: HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res. 2004 Oct 15;64(20):7426-31. [PubMed:15492266 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Wils P, Phung-Ba V, Warnery A, Lechardeur D, Raeissi S, Hidalgo IJ, Scherman D: Polarized transport of docetaxel and vinblastine mediated by P-glycoprotein in human intestinal epithelial cell monolayers. Biochem Pharmacol. 1994 Oct 7;48(7):1528-30. [PubMed:7945455 ]
  2. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K: Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res. 1999 Dec;90(12):1380-6. [PubMed:10665657 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Atpase activity, coupled to transmembrane movement of substances
Specific Function:
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name:
ABCC10
Uniprot ID:
Q5T3U5
Molecular Weight:
161627.375 Da
References
  1. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent uptake of organic anions such as 17-beta-glucuronosyl estradiol, taurocholate, triiodothyronine (T3), leukotriene C4, dehydroepiandrosterone sulfate (DHEAS), methotrexate and sulfobromophthalein (BSP). Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:
SLCO1B3
Uniprot ID:
Q9NPD5
Molecular Weight:
77402.175 Da
References
  1. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A: Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther. 2009 Feb;85(2):155-63. doi: 10.1038/clpt.2008.95. Epub 2008 May 28. [PubMed:18509327 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates sodium-independent multispecific organic anion transport. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Gene Name:
SLC22A7
Uniprot ID:
Q9Y694
Molecular Weight:
60025.025 Da
References
  1. Kobayashi Y, Ohshiro N, Sakai R, Ohbayashi M, Kohyama N, Yamamoto T: Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8. [PubMed:15901346 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transporter activity
Specific Function:
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotrexate, antiviral drugs and other xenobiotics. Confers resistance to anticancer drugs. Hydrolyzes ATP with low efficiency.
Gene Name:
ABCC1
Uniprot ID:
P33527
Molecular Weight:
171589.5 Da
References
  1. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhanel M, Spruss T, Bernhardt G, Graeff C, Farber L, Gschaidmeier H, Buschauer A, Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest. 2002 Nov;110(9):1309-18. [PubMed:12417570 ]
Drug created on June 13, 2005 07:24 / Updated on May 26, 2017 07:16